Entries |
Document | Title | Date |
20080200652 | Novel Cherkasky fusion proteins containing antibody binding proteins or the regions thereof - Disclosed are novel fusion proteins containing antibody binding regions and certain other regions. Said fusion proteins can form complexes with antibodies, which can thus be modified and be arranged three-dimensionally. Furthermore, the effect thereof can be boosted. | 08-21-2008 |
20080200653 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 08-21-2008 |
20080200654 | ANTI-A33 ANTIBODY - The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof. | 08-21-2008 |
20080214787 | MN Gene and Protein - A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression, and polymerase chain reaction (PCR) assays to detect genetic rearrangements. | 09-04-2008 |
20080214788 | INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 09-04-2008 |
20080214789 | ANTIANGIOGENESIS THERAPY OF AUTOIMMUNE DISEASE IN PATIENTS WHO HAVE FAILED PRIOR THERAPY - The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such antagonists to treat autoimmune disease in a patient who has failed prior treatment such as treatment with DMARDs or TNFα-inhibitors. | 09-04-2008 |
20080221307 | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto - The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and the antigen binding proteins, such as antibodies, that bind thereto and inhibit IL-17 ligand family members from binding to and activating IL-17 Receptor A or a receptor complex comprising IL-17 Receptor A. | 09-11-2008 |
20080227958 | BINDING PROTEINS COMPRISING IMMUNOGLOBULIN HINGE AND FC REGIONS HAVING ALTERED FC EFFECTOR FUNCTIONS - Provided herein are binding proteins comprising one or more immunoglobulin Fc region hinge, CH2, and/or CH3 domain wherein one or more hinge and/or constant region CH2 and/or CH3 domain is modified to alter the binding protein's binding affinity and/or specificity for a cognate receptor (e.g., an Fc receptor) and/or to impart one or more new binding specificity(ies) to the hinge and/or constant region that the corresponding unmodified immunoglobulin does not possess (e.g., affinity for distinct class of cognate receptor distinct from the class of cognate receptor to which the unmodified binding protein specifically binds). Binding proteins according to the present invention include, for example, modified antibodies, antibody fragments, recombinant binding proteins, and molecularly engineered binding domain-immunoglobulin fusion proteins, including small modular immunopharmaceutical products (SMIP™ products). | 09-18-2008 |
20080234469 | TUMOUR NECROSIS FACTOR BINDING LIGANDS - The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of fibrin deposition in the tumour and induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells, tumour regression, cytotoxicity and receptor binding activities of the TNF on tumour cells are unaffected. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof. | 09-25-2008 |
20080242845 | Fc variants with optimized properties - The present invention relates to Fc variants with optimized properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized properties, and methods for using Fc variants with optimized properties. | 10-02-2008 |
20080255342 | PROTEIN PURIFICATION METHOD - A method for removing contaminant DNA in a sample containing a physiologically active protein, which comprises the following steps:
| 10-16-2008 |
20080255343 | CHIMERIC ANTIBODIES - The present invention provides a chimeric antibody or an antigen-binding portion thereof. The antigen-binding portion comprises at least two complementarity determining regions (CDR) and at least three framework regions, wherein at least one CDR is a New World primate CDR | 10-16-2008 |
20080262203 | NOVEL COMPOUNDS - The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to (cross react with) human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78. | 10-23-2008 |
20080269466 | Modified Antibody Fragments - The present invention relates to a new class of modified antibody fragments. The present invention provides an antibody fragment to which one or more effector molecules is attached characterized in that the native interchain disulphide bond between the heavy (CHI) and light (CL) chain constant regions is absent and the heavy chain (CHI) and light chain (CL) constant regions are linked by an interchain disulphide bond between a pair of engineered cysteines, one in the light chain constant (CL) region and the other in the heavy chain constant (CHI) region. | 10-30-2008 |
20080269467 | Anti-IL-17 Antibodies - Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful in particular for treating autoimmune, inflammatory, cell proliferative and developmental disorders. | 10-30-2008 |
20080275220 | METHOD FOR STABILIZING A PROTEIN - The invention relates to a method for stabilizing an aqueous protein solution against exogenous stress and to the use of a container for stabilizing an aqueous protein solution. | 11-06-2008 |
20080281082 | HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. | 11-13-2008 |
20080287657 | Alteration of Fc-fusion protein serum half-lives by mutagenesis - The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein. | 11-20-2008 |
20080293921 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies - The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. In one embodiment, the invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them. | 11-27-2008 |
20080312417 | UCP5 - The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. | 12-18-2008 |
20090012268 | NOVEL MONOCLONAL THYROID STIMULATING OR BLOCKING ANTIBODIES, PEPTIDE SEQUENCES CORRESPONDING TO THEIR VARIABLE REGIONS, AND THEIR USES IN DIAGNOSTIC, PREVENTIVE AND THERAPEUTIC MEDICINE - Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab′) | 01-08-2009 |
20090012269 | HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods. | 01-08-2009 |
20090018314 | GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS - Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases. | 01-15-2009 |
20090023900 | Anti-AlphaVBeta3 Recombinant Human Antibodies, Nucleic Acids Encoding Same - The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to α | 01-22-2009 |
20090030186 | PICHIA METHANOLICA SECRETORY SIGNAL | 01-29-2009 |
20090030187 | MACROMOLECULES COMPRISING A THIOETHER CROSS-LINK - The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least one thioether cross-link that specifically bind to particular antigens. The present invention also provides a composition comprising a macromolecule substantially free of a denaturing reagent, wherein the macromolecule comprises at least one thioether cross-link. In addition, the present invention provides a method for producing the macromolecules and compositions of the invention. | 01-29-2009 |
20090048432 | ANTI-IL-20 ANTIBODY AND ITS USE IN TREATING IL-20 ASSOCIATED INFLAMMATORY DISEASES - This invention features an antibody specifically binding to human IL-20 (e.g., mAb 7E and a equivalent thereof) and its use in treating an IL-20 associated inflammatory disease, such as atherosclerosis, RA, psoriasis, psoriatic arthritis, bacteria-induced gastric ulcer, and acute renal failure. | 02-19-2009 |
20090054630 | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors - Antibodies that bind CCX-CKR2 are described. | 02-26-2009 |
20090054631 | COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKIN'S LYMPHOMA - The present invention is directed to compositions of matter useful for the treatment of non-Hodgkin's lymphoma in mammals and to methods of using those compositions for the same. | 02-26-2009 |
20090069544 | HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. | 03-12-2009 |
20090076248 | Plus end-directed microtubule motor required for chromosome congression - The invention provides isolated nucleic acid and amino acid sequences of | 03-19-2009 |
20090076249 | Antibodies against CD38 for treatment of multiple myeloma - Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 03-19-2009 |
20090076250 | Substance that Specifically Recognizes PD-1 - Compounds that can recognize selectively both PD-1 protein and a membrane protein co-existing with PD-1 on a cell membrane, and can transmit a suppressive signal of PD-1. The compounds are useful for medical treatment and/or prevention of diseases caused by immune abnormality. | 03-19-2009 |
20090082549 | FcE-PE chimeric protein for targeted treatment of allergy responses a method for its production and pharmaceutical compositions containing the same - The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the FcεRI receptor by a chimeric cytotoxin FC | 03-26-2009 |
20090105457 | NOVEL HEMOPOIETIN RECEPTOR PROTEIN, NR12 - A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was detected in tissues containing hematopoietic cells. NR12 is a novel hemopoietin receptor molecule involved in the regulation of immune system and hematopoiesis in vivo. Thus, NR12 is useful in the search for novel hematopoietic factors that functionally bind to the NR12 receptor, and in the development of therapeutic drugs for diseases associated with immunity or hematopoiesis. | 04-23-2009 |
20090105458 | NOVEL HEMOPOIETIN RECEPTOR PROTEIN, NR12 - A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was detected in tissues containing hematopoietic cells. NR12 is a novel hemopoietin receptor molecule involved in the regulation of immune system and hematopoiesis in vivo. Thus, NR12 is useful in the search for novel hematopoietic factors that functionally bind to the NR12 receptor, and in the development of therapeutic drugs for diseases associated with immunity or hematopoiesis. | 04-23-2009 |
20090105459 | NOVEL HEMOPOIETIN RECEPTOR PROTEIN, NR12 - A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was detected in tissues containing hematopoietic cells. NR12 is a novel hemopoietin receptor molecule involved in the regulation of immune system and hematopoiesis in vivo. Thus, NR12 is useful in the search for novel hematopoietic factors that functionally bind to the NR12 receptor, and in the development of therapeutic drugs for diseases associated with immunity or hematopoiesis. | 04-23-2009 |
20090111972 | NOVEL HEMOPOIETIN RECEPTOR PROTEIN, NR12 - A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was detected in tissues containing hematopoietic cells. NR12 is a novel hemopoietin receptor molecule involved in the regulation of immune system and hematopoiesis in vivo. Thus, NR12 is useful in the search for novel hematopoietic factors that functionally bind to the NR12 receptor, and in the development of therapeutic drugs for diseases associated with immunity or hematopoiesis. | 04-30-2009 |
20090131638 | ANTI-MYOSTATIN ANTIBODIES - Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species. | 05-21-2009 |
20090131639 | ANTIBODY-CONTAINING SOLUTION FORMULATIONS - Antibody-containing solution formulations including a sugar as a stabilizer. Said solution formulations can further include a surfactant as a stabilizer. | 05-21-2009 |
20090137782 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 05-28-2009 |
20090137783 | CNGH0010 Specific Polynucleotides, Polypeptides, Antibodies, Compositions, Methods and Uses - Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, psoriasis, rheumatoid arthritis, emphysema, asthma, diabetes, autoimmune thyroiditis, inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, different types of dermatitis including allergic dermatitis, contact dermatitis, actinic keratosis, wound healing, scar formation, various renal diseases, various respiratory diseases, various diseases of reproductive organs, such as endometriosis, melanoma, squamous cell carcinoma, ovarian cancer, breast cancer, lung cancer, colon cancer, prostate cancer, renal cell carcinoma, Grave's diseases and other inflammatory and hyperproliferative diseases. | 05-28-2009 |
20090149635 | ANTIBODIES TO HUMAN ZCYTOR17 LIGAND - The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 06-11-2009 |
20090149636 | CYTOKINE PROTEIN FAMILY - The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides. | 06-11-2009 |
20090156788 | ENGINEERED ANTI-IL-23 ANTIBODIES - Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 06-18-2009 |
20090163699 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 06-25-2009 |
20090182126 | GUANYLATE-BINDING PROTEIN - A member of the guanylate-binding protein family, designated GBP-4, is provided. Also provided are isolated nucleic acid encoding GBP-4, vectors and host cells containing such nucleic acid molecule, and a method for producing the GBP-4 recombinantly. | 07-16-2009 |
20090182127 | Production of Bispecific Antibodies - Bispecific antibodies comprising (a) a first light-heavy chain pair having specificity for a first target and a sufficient number of substitutions in its heavy chain constant domain with respect to a corresponding wild-type antibody of the same isotype to significantly reduce the formation of first heavy chain-first heavy chain dimers and (b) a second light-heavy chain pair comprising a heavy chain having a sequence that is complementary to the sequence of the first pair heavy chain sequence with respect to the formation of intramolecular ionic interactions, wherein the first pair or second pair comprises a substitution in the light chain and complementary substitution in the heavy chain that reduces the ability of the light chain to interact with the heavy chain of the other light chain-heavy chain pair are provided. Methods of producing such antibodies in one or more cells also are provided. | 07-16-2009 |
20090187007 | ANTI-HER2 ANTIBODY VARIANTS - The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains | 07-23-2009 |
20090192294 | MAGI POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES - MAGI polypeptides, polynucleotides, antibodies, and methods for producing the same by recombinant techniques are disclosed. Also disclosed are methods for utilizing MAGI polypeptides and polynucleotides in diagnostic assays. | 07-30-2009 |
20090198044 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 08-06-2009 |
20090203886 | HUMANIZED ANTI CD20 MONOCLONAL ANTIBODY - The present invention provides a humanized anti human CD20 monoclonal antibody, selection criteria therefor, humanized antibodies selected using that criteria and showing biological characteristics suitable for use as pharmaceuticals. | 08-13-2009 |
20090209732 | Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same - The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 08-20-2009 |
20090215992 | Dual variable domain immunoglobulin and uses thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 08-27-2009 |
20090221802 | SOLUBLE ZALPHA11 CYTOKINE RECEPTORS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 09-03-2009 |
20090221803 | MODULATION OF ANTIBODY EFFECTOR FUNCTION BY HINGE DOMAIN ENGINEERING - The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or CIq. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes. | 09-03-2009 |
20090234103 | NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION - The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization. | 09-17-2009 |
20090234104 | Modified Fc molecules - The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. | 09-17-2009 |
20090234105 | Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition - The present invention provides for a practical, universal and efficient method to ligate two large macromolecules (e.g., proteins) using the alkyne-azide 1,3-dipolar cycloaddition reaction to produce a conjugated macromolecule, such as a multivalent scFv. The present invention also provides for conjugate macromolecules comprising a plurality of macromolecule components cross-linked through at least one linking group comprising at least one 1,2,3-triazole moiety, wherein at least 50 percent of the macromolecule components in the conjugate macromolecule has only one site available for cross-linking. | 09-17-2009 |
20090240036 | Anti-IL-23 Antibodies - The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease. | 09-24-2009 |
20090240037 | HUMANIZED ANTIBODIES AND METHODS OF HUMANIZING ANTIBODIES - Humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which are useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis are disclosed. Methods of making the humanized, chimeric and human anti-CD20 antibodies are disclosed. A humanized anti-HSG (histamine-succinyl-glycyl) monoclonal antibody designated h679 which binds with high affinity to molecules containing the moiety histamine-succinyl-glycyl (HSG), and methods of making the humanized anti-HSG antibody also are disclosed. | 09-24-2009 |
20090259026 | Ligand - The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity. | 10-15-2009 |
20090264627 | ENHANCING THE CIRCULATING HALF-LIFE OF ANTIBODY-BASED FUSION PROTEINS - Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered amino acid sequence in the junction region has a greater circulating half-life when administered to a mammal. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal. | 10-22-2009 |
20090270597 | ARTIFICIAL ANTIBODY POLYPEPTIDES - A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, k | 10-29-2009 |
20090275734 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 11-05-2009 |
20090275735 | MONOCLONAL ANTIBODIES TO HUMAN CTLA-8 (IL-17A) - Human CTLA-8 protein, antibodies that specifically bind to human CTLA-8, and nucleic acids encoding human CTLA-8. Methods of using these molecules and diagnostic kits are also provided. | 11-05-2009 |
20090286962 | CHIMERIC ANTIBODIES WITH PART NEW WORLD PRIMATE BINDING REGIONS - The present invention provides a chimeric antibody polypeptide comprising an antigen binding site, wherein the antigen binding site comprises a human variable domain having at least one New World Primate CDR. | 11-19-2009 |
20090299038 | ANTI-HDLK-1 ANTIBODY HAVING AN ANTITUMOR ACTIVITY IN VIVO - The present invention provides antibodies specifically against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies), a fragments of the antibodies, hybridomas that produce the antibodies, a complex of the antibody or antibody fragment and an agent, a pharmaceutical composition comprising the antibody and the like, a tumor therapeutic agent, a tumor angiogenesis inhibitor, a tumor diagnostic agent, a method for detecting tumor, a kit for detecting and/or diagnosing tumor, etc. | 12-03-2009 |
20090299039 | ANTI-A33 ANTIBODY - The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M 165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof. | 12-03-2009 |
20090318672 | ANTIBODIES TO PRO352 - The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 12-24-2009 |
20090326203 | Framework Selection - The present invention relates to improved methods for the selection of appropriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such acceptor frameworks. | 12-31-2009 |
20090326204 | INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 12-31-2009 |
20090326205 | ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO - The present invention provides an antibody specifically against hDlk-1 and having anti-tumor activity in vivo (an anti-hDlk-1 antibody), a fragment of the antibody, a hybridoma that produces the antibody, a complex of the antibody or antibody fragment and an agent, a pharmaceutical composition comprising the antibody and the like, a tumor therapeutic agent, a tumor angiogenesis inhibitor, a tumor diagnostic agent, a method for detecting a tumor, a kit for detecting and/or diagnosing a tumor, etc. | 12-31-2009 |
20090326206 | Single-chain Multiple Antigen-binding Molecule, Its Preparation and Use - The present invention relates to a single-chain, multiple antigen-binding molecule with diverse variable domains of a heavy and of a light chain of an immunoglobulin, which are connected in the form of a VH-VL construct, which are in turn connected together via a peptide, and to the preparation and use thereof as pharmaceutical or diagnostic aid. | 12-31-2009 |
20100010201 | Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods - The present invention relates in general to metalloproteinase inhibitors and to polynucleotides encoding such inhibitors. In particular, the invention relates to novel mammalian inhibitors of metalloproteinase, which are designated as type three or TIMP-3, to fragments, derivatives, and analogs thereof, and to polynucleotides encoding the same. Novel methods of producing such compositions and novel methods of using such compositions are also provided. | 01-14-2010 |
20100016556 | METHOD FOR MAKING HUMANIZED ANTIBODIES - Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided. | 01-21-2010 |
20100016557 | HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 01-21-2010 |
20100022757 | Process for the Purification of FC-Containing Proteins - The invention relates to a process for the purification of an Fc-containing protein based on cation exchange chromatography. | 01-28-2010 |
20100036101 | ANTIBODIES AGAINST NON FUNCTIONAL P2X7 RECEPTOR - A recombinant or synthetic antibody or fragment thereof, said antibody or fragment thereof including three complementarity determining regions (CDR1 | 02-11-2010 |
20100041873 | ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES - Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells T | 02-18-2010 |
20100048877 | NOVEL MULTIVALENT IMMUNOGLOBULINS - The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of said immunoglobulin determining binding to an epitope of said cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to said epitope, its use and methods for producing it. | 02-25-2010 |
20100056759 | Methods and Compositions for Efficient Removal of Protein A from Binding Molecule Preparations - The present invention features methods for reducing protein A contamination in a binding molecule preparation, e.g., a therapeutic binding molecule preparation, comprising residual protein A, or fragments thereof. | 03-04-2010 |
20100056760 | SIALOADHESIN FACTOR-2 ANTIBODIES - Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents. | 03-04-2010 |
20100063258 | FUSION PROTEIN CONSTRUCTS - Polypeptide linkers with defined tertiary structures, usually of defined alpha helical structure, are used to join two domains in a fusion protein. In one embodiment of the invention, a method is provided for the cell-free synthesis of the fusion protein. | 03-11-2010 |
20100069615 | Regulation of Human Transmembrane Serine Protease - Reagents that regulate human transmembrane serine protease activity and reagents that bind to human transmembrane serine protease gene products can be used to regulate extracellular matrix degradation. Such regulation is particularly useful for treating COPD, metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections. | 03-18-2010 |
20100076177 | Hybrid antibodies - Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs. | 03-25-2010 |
20100076178 | Dual Variable Domain Immumoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 03-25-2010 |
20100076179 | ANTIBODIES TO MAMMALIAN CYTOKINE-LIKE FACTOR 7 - Novel mammalian zcyto7 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies. | 03-25-2010 |
20100081793 | THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN - The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury. | 04-01-2010 |
20100081794 | Modified Glycoproteins and Uses Thereof - The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value. | 04-01-2010 |
20100081795 | RG1 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications. | 04-01-2010 |
20100081796 | BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIES - The present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies. | 04-01-2010 |
20100093977 | Altered Antibodies - This invention relates to engineering of antibodies and more specifically provides altered antibodies of the IgG class to which one or more effector molecules are attached. The invention further relates to methods for the production of such conjugated antibodies. | 04-15-2010 |
20100093978 | DKK-RELATED PROTEINS - Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 04-15-2010 |
20100093979 | Fc Polypeptides With Novel Fc Ligand Binding Sites - The present invention relates to Fc polypeptides with novel Fc receptor binding sites, and their application, particularly for therapeutic purposes. | 04-15-2010 |
20100093980 | Methods of Humanizing Immunoglobulin Variable Regions Through Rational Modification Of Complementarity Determining Residues - The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies. | 04-15-2010 |
20100099853 | Multivalent Antibody Constructs - The present invention relates to a multivalent F | 04-22-2010 |
20100105874 | BISPECIFIC ANTIBODIES AND METHODS FOR PRODUCTION THEREOF - The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfidebond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention. | 04-29-2010 |
20100113747 | Coupling of Antibody Polypeptides at the C-Terminus - The present invention relates to a process for dimerization of antibody fragments, antibody fragment dimers, pharmaceutical compositions comprising antibody fragment dimers as well as their use in medicaments for therapeutic applications. The methods described can advantageously be used for producing bispecific antibodies and/or bispecific fragments thereof. | 05-06-2010 |
20100113748 | SOLUBLE IL-17RCX4 AND METHODS OF USING IN INFLAMMATION - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation. | 05-06-2010 |
20100121035 | PURIFICATION OF IMMUNOGLOBULINS - The present invention relates to a separation matrix comprised of a porous or non-porous support to which ligands have been immobilised, wherein said ligands comprise at least one aliphatic sulfamide. The invention also relates to a chromatography column that contains the described separation matrix, as well as to a method of isolating immunoglobulins, such as IgG, Fab fragments, fusion proteins containing immunoglobulins etc, by adsorption to a separation matrix that comprises the aliphatic sulfamide ligands of the invention. | 05-13-2010 |
20100125130 | TUMOUR NECROSIS FACTOR BINDING LIGANDS - The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of fibrin deposition in the tumour and induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells, tumour regression, cytotoxicity and receptor binding activities of the TNF on tumour cells are unaffected. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof. | 05-20-2010 |
20100130728 | TACI-IMMUNOGLOBULIN FUSION PROTEINS - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors. | 05-27-2010 |
20100145024 | LONG WAVELENGTH ENGINEERED FLUORESCENT PROTEINS - Engineered fluorescent proteins, nucleic acids encoding them and methods of use. | 06-10-2010 |
20100145025 | Recombinant Mouse-Human Chimeric Fab Against Hepatitis B Surface Antigen - The invention relates to a recombinant chimeric Fab antibody comprising a recombinant Fd and a recombinant chimeric light chain which binds to hepatitis B surface antigen with high affinity, generated by fusing variable region genes (V | 06-10-2010 |
20100145026 | Antibody for ADCC And Inducing Cytokine Production - The invention concerns chimeric monoclonal antibodies, humanized or human produced in selected cell lines, said antibodies exhibiting high affinity for the CD16 receptor of effector cells of the immune system and hence capable of inducing high ADCC, but also the property of inducing cytokine and interleukin secretion, in particular IFNγ, which can enhance the ADCC activity of effector cells and hence be used for treating cancers and infections by pathogenic agents. | 06-10-2010 |
20100145027 | Compositions and Methods for the Diagnosis and Treatment of Tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 06-10-2010 |
20100145028 | Increasing The Production Of Recombinant Antibodies In Mammalian Cells By Site-Directed Mutagenesis - The present invention relates to a reliable, reproducible method for improving the producibility of an antibody. More specifically, this invention provides a method for modifying the heavy chain of an antibody to improve its producibility in eukaryotic cells. Additionally, the method of the invention may improve both antibody producibility and one or more antigen binding characteristics. The invention further provides modified antibodies which are better produced and which have either no change in their antigen binding characteristics or exhibit improved antigen binding characteristics. | 06-10-2010 |
20100145029 | ENHANCED CAPACITY AND PURIFICATION OF ANTIBODIES BY MIXED MODE CHROMATOGRAPHY IN THE PRESENCE OF AQUEOUS-SOLUBLE NONIONIC ORGANIC POLYMERS - This invention relates to the use of mixed mode chromatography for purification of at least one intact non-aggregated antibody from a mixture containing intact non-aggregated antibodies and undesirable materials, including fragmented or aggregated antibodies, host cell proteins, DNA, endotoxin, and/or virus. This invention further relates to the integration of such a method into a multi-step procedure with other fractionation methods for purification of antibodies suitable for in vivo applications. | 06-10-2010 |
20100152426 | APO-2 RECEPTOR FUSION PROTEINS - Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided. | 06-17-2010 |
20100152427 | NUCLEIC ACID ENCODING A NOVEL DP RECEPTOR PROTEIN AND METHODS OF USE THEREOF - Described herein is a novel member of the prostanoid receptor family, a guinea pig prostaglandin D2 receptor. Described are the receptor, the nucleic acid that encodes it, and various uses for both. | 06-17-2010 |
20100168393 | Antibody Polypeptide Libray Screening and Selected Antibody Polypeptides - The present invention provides further developments in the screening of antibody polypeptide libraries. The invention also provides novel isolated antibody polypeptides obtainable by the methods of the invention. | 07-01-2010 |
20100168394 | Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof - The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease. | 07-01-2010 |
20100168395 | NOVEL POLYPEPTIDE, AN AFFINITY CHROMATOGRAPHY MATERIAL, AND A METHOD FOR SEPARATING AND/OR PURIFYING IMMUNOGLOBULIN - [Object] The aim of the present invention is to develop a novel immunoglobulin binding polypeptide, the loss and formation of whose native three dimensional structure can be controlled under the conditions where unwanted effects such as damages, loss of functions or unintended functions do not occur to immunoglobulin (pH 5-9, lower than 60° C.), and use thereof as a ligand coupled to an affinity chromatography support. | 07-01-2010 |
20100174050 | EXPRESSION OF POLYPEPTIDES FROM THE NUCLEAR GENOME OF OSTREOCOCCUS SP - A method of producing at least one polypeptide from the nuclear genome of | 07-08-2010 |
20100184958 | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR - Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF. | 07-22-2010 |
20100184959 | Polypeptide Variants - The present invention relates to methods for selecting, obtaining or producing Fc variant polypeptides which show altered recognition for an Fc ligand (e.g., FcγR, CIq). Additionally, the Fc variant polypeptides may have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variant polypeptides particularly for therapeutic purposes. | 07-22-2010 |
20100190962 | NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS AND USES THEREOF - Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers. | 07-29-2010 |
20100190963 | Stirred Tank Reactor And Method - Container for sample preparation or processing, such as biomass culturing or processing, and optionally sample purification. In certain embodiments, the reactor is a bioreactor that includes a stirred cell device that simulates a tangential flow filter to reduce or eliminate clogging that can be caused by the solids generated. In certain embodiments, the solids comprise a precipitate or floc or beads, such as one that includes a polymer that binds the biomolecule(s) of interest, and impurities. In its method aspects, embodiments disclosed herein include purification and isolation of biomolecules of interest derived from cell culture fluids. The methods include carrying out sample preparation or processing in a container, culturing a biomass; generating solids by precipitating or flocculating a biomolecule of interest from the cultured broth; preventing the solids from settling in the container by agitation; and purification, such as by eluting the biomolecule of interest and filtering the same. | 07-29-2010 |
20100190964 | Antibodies to human ErbB4 - The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing the proliferation or migration of smooth muscle cells. | 07-29-2010 |
20100197895 | ANTIBODIES TO HUMAN TUMOR NECROSIS FACTOR RECEPTOR - Tumor necrosis factors and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human tumor necrosis factor receptor designated as “Ztnfr12.” | 08-05-2010 |
20100197896 | FUNCTIONAL HUMANIZATION OF COMPLEMENTARITY DETERMINING REGIONS (CDRS) - Current humanization approaches for immunoglobulins focus mostly on modifying the framework regions into human sequences. Herein is provided a method for humanizing antibody complementarity-determining regions (CDRs) through functional humanization to reduce the potential immunogenicity of non-human CDR-containing antibodies. CDRs with high sequence homology to the parent CDR are identified from a database of human CDR sequences. One or more human CDRs that are highly homologous to the parent CDR sequence can be used to replace the corresponding CDRs of murine immunoglobulins (or their humanized, or re-engineered versions). Human CDRs that improve or have minimal effects on the antigen binding affinity and specificity are adopted. | 08-05-2010 |
20100197897 | BINDING MOLECULES - The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. | 08-05-2010 |
20100204453 | ANTIBODIES TO TUMOR ASSOCIATED PROTEINS - A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization. | 08-12-2010 |
20100204454 | Fc Variants with altered binding to FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 08-12-2010 |
20100210825 | ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners. | 08-19-2010 |
20100216975 | Framework-Shuffling Of Antibodies - The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining regions (CDRs) from a donor antibody fused in frame to framework regions from a sub-bank of framework regions. The invention also provides method of producing improved humanized antibodies. The present invention also provides antibodies produced by the methods of the invention. | 08-26-2010 |
20100222555 | Monoclonal antibodies that neutralize botulinum neurotoxin - This invention provides antibodies that specifically bind to botulinum neurotoxin type A (BoNT/A) and/or botulinum neurotoxin type B (BoNT/B) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. Also included in the invention are diagnostic and therapeutic assays directed to botulinum neurotoxins. | 09-02-2010 |
20100222556 | ANTIBODIES TO CYTOKINE RECEPTOR ZALPHA11 - Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 09-02-2010 |
20100222557 | CYTOKINE ZALPHA11LIGAND ANTIBODIES - Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described. | 09-02-2010 |
20100234570 | Ligand - The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity. | 09-16-2010 |
20100234571 | FC VARIANTS WITH ALTERED BINDING TO FCRN - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 09-16-2010 |
20100234572 | Fc Variants with altered binding to FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 09-16-2010 |
20100234573 | Fc Variants with altered binding to FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 09-16-2010 |
20100234574 | Fc Variants with altered binding to FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 09-16-2010 |
20100234575 | FC VARIANTS WITH ALTERED BINDING TO FCRN - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 09-16-2010 |
20100234576 | HUMAN TOLL HOMOLOGUES - The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein. | 09-16-2010 |
20100240872 | ANTI-Muc 17 ANTIBODY - An antibody that binds to Mucin17 (Muc17) is disclosed. The antibody of the present invention preferably binds to the peptide of SEQ ID NO:3 and does not bind to the peptide of SEQ ID NO:4 or the peptide of SEQ ID NO:5. Also disclosed are an anti-cancer agent, preferably an anti-cancer agent for pancreatic cancer, which comprises the antibody of the present invention, as well as a method of diagnosing cancer using the antibody of the present invention, preferably the antibody of the present invention that does not bind to the secreted-form of Muc17. | 09-23-2010 |
20100240873 | LIGAND (ACT-4-L) TO A RECEPTOR ON THE SURFACE OF ACTIVATED CD4+ TCELLS - The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4 | 09-23-2010 |
20100240874 | METHOD FOR PURIFYING CANCER-SPECIFIC PROLIFERATING CELL NUCLEAR ANTIGEN - An isolated antibody that binds a cancer specific Proliferating Cell Nuclear Antigen (csPCNA) that binds to the amino acid sequence LeuLysGlnLeuAspAlaGlnGlnThrGlnLeuArgIle AspSerPhePheArgLeuAlaGlnGlnGluLysGluAspAlaLysArg (SEQ ID No. 1). An immunoassay that utilizes an isolated antibody that binds a form of csPCNA that binds to the SEQ ID No. 1 to identify the presence of csPCNA in a sample. | 09-23-2010 |
20100240875 | Antibodies That Specifically Bind to Reg IV - The present invention relates to antibodies and related molecules that specifically bind to Reg IV. Such antibodies have uses, for example, in the prevention and treatment of gastrointestinal tract cancers, inflammatory bowel disorders, and diabetes. The invention also relates to nucleic acid molecules encoding anti-Reg IV antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially gastrointestinal tract cancers, inflammatory bowel disorders, and diabetes, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to Reg IV. | 09-23-2010 |
20100249380 | Modulating Immune Responses - The invention provides methods for modulating the immune system using anti-CD83 antibodies that can influence CD83 function. | 09-30-2010 |
20100249381 | Method for Purifying FC-Fusion Proteins - The invention relates to a method for the purification of Fc-fusion via blue dye affinity chromatography, in particular for the reduction of the amount of free Fc-moieties in an Fc-fusion proteins preparation. | 09-30-2010 |
20100249382 | MODIFIED Fc MOLECULES - The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties. | 09-30-2010 |
20100261887 | TACI-IMMUNOGLOBULIN FUSION PROTEINS FOR TREATMENT OF RELAPSING MULTIPLE SCLEROSIS - The invention relates to TACI-Immunoglobulin fusion proteins for the treatment of relapsing multiple sclerosis. | 10-14-2010 |
20100267932 | PROCESS FOR THE PURIFICATION OF FC-FUSION PROTEINS - The invention relates to a process for the purification of an Fc-fusion protein having a pI between 6.9 and 9.5 comprising protein A or G affinity chromatography, cation exchange chromatography, anion exchange chromatography and hydroxyapatite chromatography. | 10-21-2010 |
20100267933 | PURIFICATION OF PROTEINS - The present invention relates to a selectively soluble polymer capable of binding to one or more constituents in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and is rendered insoluble and precipitates out of solution upon a change in the process conditions. While in its solubilized state, the polymer is capable of binding to a selected entity within the stream such as impurities (DNA, RNA, host cell protein, endotoxins, etc) in a cell broth and remains capable of binding to that entity even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered and further processed. | 10-21-2010 |
20100267934 | STABLE IGG4 ANTIBODIES - The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370). | 10-21-2010 |
20100267935 | ANTIBODY HAVING INHIBITORY EFFECT ON AMYLOID FIBRIL FORMATION - Disclosed is an antibody having a high inhibitory effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided. | 10-21-2010 |
20100267936 | PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES - The present invention concerns a process by which a misfold in an Fc fusion molecule can be prevented or corrected. In one embodiment, the process comprises (a) preparing a pharmacologically active compound comprising an Fc domain; (b) treating the fusion molecule with a copper (II) halide; and (c) isolating the treated fusion molecule. The pharmacologically active compound can be an antibody or a fusion molecule comprising a pharmacologically active domain and an Fc domain. The preferred copper (II) halide is CuCl | 10-21-2010 |
20100273988 | ANTI-CANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT - A monoclonal antibody having a neutralizing activity on HB-EGF is disclosed. The monoclonal antibody of the present invention is preferably an antibody that does not bind to the HB-EGF protein on the cell surface of HB-EGF-expressing cells. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the monoclonal antibody of the present invention as an active ingredient, and a method of treating cancer, the method comprising administering the monoclonal antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, bladder cancer, and brain tumors. | 10-28-2010 |
20100273989 | ANGIOTENSIN CONVERTING ENZYME HOMOLOG AND USES THEREFOR - The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostic methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions. | 10-28-2010 |
20100273990 | Notch-based fusion proteins and uses thereof - This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide. | 10-28-2010 |
20100280227 | POLYPEPTIDES THAT BIND BR3 AND USES THEREOF - The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods. | 11-04-2010 |
20100286374 | METHOD FOR MAKING ANTIBODY FC-HETERODIMERIC MOLECULES USING ELECTROSTATIC STEERING EFFECTS - The invention relates to methods of making Fc-heterodimeric proteins or polypeptides. The invention also relates to the Fc-heterodimeric proteins or polypeptides themselves, including the individual polypeptide components that comprise the heterodimer. Nucleic acids encoding such polypeptides, expression vectors, and host cells. Moreover, the invention relates to pharmaceutical compositions comprising one of more Fc-heterodimeric proteins or polypeptides. | 11-11-2010 |
20100292441 | Antibodies that specifically bind to GMAD - The present invention relates to antibodies and related molecules that immunospecifically bind to GMAD. Such antibodies have uses, for example, in the prevention and treatment of both insulin- and non insulin-dependent diabetes mellitus (i.e. Type I and Type II diabetes) and other related disorders. The invention also relates to nucleic acid molecules encoding anti-GMAD antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially diabetes and other related disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to GMAD. | 11-18-2010 |
20100292442 | ANTI-IL-17 RECEPTOR A NEUTRALIZING ANTIBODIES - The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and the antigen binding proteins, such as antibodies, that bind thereto and inhibit IL-17 ligand family members from binding to and activating IL-17 Receptor A or a receptor complex comprising IL-17 Receptor A. | 11-18-2010 |
20100298542 | Modified Antibody Constant Region - The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fcγ receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics. | 11-25-2010 |
20100298543 | MAMMALIAN ZCYTOR 11 - Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in pancreas, small intestine, colon and thymus. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of these organs. | 11-25-2010 |
20100298544 | CDR-GRAFTED ANTI-TISSUE FACTOR ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides CDR-grafted antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants and are thus useful in the treatment and prophylaxis of human thrombotic disease. The invention also provides methods of making the CDR-grafted antibodies and pharmaceutical compositions for the attenuation or prevention of coagulation. | 11-25-2010 |
20100305306 | NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 12-02-2010 |
20100311954 | Optimized Proteins that Target Ep-CAM - Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided. | 12-09-2010 |
20100317835 | Anti-Adam-15 Antibodies and Utilization of the Same - A remedy for cancer obtained from a different viewpoint from the viewpoints employed in developing the existing anticancer drugs, i.e., focusing on the intercellular adhesion of cancer cells. Namely, provided is a remedy for cancer with fewer side effects which inhibits the proliferation of cancer cells and the intercellular adhesion of cancer cells. Also provided is an antibody, which recognizes the disintegrin domain of ADAM-15 and is usable as an anticancer agent, and so on. An antibody, which recognizes the disintegrin domain of ADAM-15 but does not recognize the RGD sequence or loop region in the disintegrin domain of ADAM-15, and so on; an antibody, which inhibits ADAM-15 and integrin αvβ3-dependent cell adhesion, and so on; and an antibody, which inhibits ADAM-15 and integrin αvβ1-dependent cell adhesion, and so on. | 12-16-2010 |
20100324270 | Compositions and Methods of Use for Modulators of Polypeptides and Polynucleotides in Treating Breast Cancer and Melanoma - This invention relates to the polynucleotides and the encoded polypeptides, including novel sequences, of human or non-human primate genes that are amplified in breast and/or other tumor tissues melanoma, as compared to the corresponding normal tissue. The invention also relates to modulators of such polynucleotides and polypeptides, for example, antibodies, that specifically bind to and/or interfere with the activity of this polypeptide, polynucleotide, its fragments, variants, and antagonists. The invention further relates to compositions containing such a polypeptide, polynucleotide, or modulators thereof and uses of such compositions in methods of treating or preventing cancer, by detecting this polynucleotide, polypeptide, or antibodies thereto in patient samples. The invention also provides diagnostic tests for breast cancer and melanoma, by identifying polypeptides and polynucleotides encoded by the cDNA sequence of the invention that correlate with those disorders. | 12-23-2010 |
20100324271 | PHAGE-DISPLAYING SINGLE-CHAIN ANTIBODY CAPABLE OF RECOGNIZING NON-REDUCED MANNOSE RESIDUE - It is an object of the present invention to provide antibodies which recognize non-reducing mannose residues. The present invention provides antibodies recognizing non-reducing mannose residues, which are obtained through screening of phage-display library of human scFvs by using, as an antigen, Man3-DPPE which is an artificial glycolipid synthesized from mannotriose and dipalmitoylphosphatidylethanolamine by reductive amination. | 12-23-2010 |
20100324272 | PANCREATIC CANCER GENES - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 12-23-2010 |
20100331526 | CAPTURE PURIFICATION PROCESSES FOR PROTEINS EXPRESSED IN A NON-MAMMALIAN SYSTEM - Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. Resin regeneration methods are also provided. | 12-30-2010 |
20100331527 | Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format - A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A. | 12-30-2010 |
20110003972 | STABILIZING POLYPEPTIDES WHICH HAVE BEEN EXPOSED TO UREA - Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea. | 01-06-2011 |
20110009599 | APO-2 RECEPTOR POLYPEPTIDES - Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided. | 01-13-2011 |
20110009600 | Recombinant Antibody Composition - The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient. | 01-13-2011 |
20110009601 | LABELED PROTEIN AND METHOD FOR OBTAINING THE SAME - It is an object of the present invention to obtain a labeled protein, and specifically, to separate a labeled protein and the same unlabeled protein. There is provided a labeled protein including: a protein to be labeled having a target protein, at least one or more affinity interaction domains for binding to an affinity support, and at least one or more labeling sites; and a labeling reagent binding to at least one of the labeling sites; wherein the affinity of the labeled protein for the affinity support is difference from that of the protein to be labeled for the affinity support. | 01-13-2011 |
20110021757 | TRANSGENIC SILKWORM CAPABLE OF PRODUCING ANTIBODY AND METHOD FOR PRODUCTION THEREOF - The present inventors produced transgenic silkworms which comprise a promoter of a DNA encoding a protein specifically expressed in the silk gland and a DNA encoding a recombinant antibody whose expression is regulated directly or indirectly by the promoter, and which secrete the recombinant antibody into the silk gland. The recombinant antibodies produced from the silk gland of the transgenic silkworms were confirmed to be active. | 01-27-2011 |
20110021758 | HYBRID ANTIBODIES - Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs. | 01-27-2011 |
20110028694 | METHODS TO EXPRESS RECOMBINANT PROTEINS FROM LENTIVIRAL VECTORS - Lentivector constructs for expression of recombinant proteins, polypeptides or fragments thereof and methods of making the same are described. The lentivectors typically have a self-processing cleavage sequence between a first and second protein or polypeptide coding sequence allowing for expression of a functional protein or polypeptide under operative control of a single promoter and may further include an additional proteolytic cleavage sequence which provides a means to remove the self-processing cleavage sequence from the expressed protein or polypeptide. The vector constructs find utility in methods relating to enhanced production of biologically active proteins, such as immunoglobulins or fragments thereof in vitro and in vivo. | 02-03-2011 |
20110028695 | METHOD FOR OBTAINING POLYPEPTIDE CONSTRUCTS COMPRISING TWO OR MORE SINGLE DOMAIN ANTIBODIES - The present invention relates to methods for obtaining a polypeptide construct directed against one or more antigens and/or epitopes and having one or more desired characteristics, wherein the polypeptide construct comprises at least two single domain antibodies. The methods of the present invention involve producing a diversity of polypeptide constructs that are structural variants and screening the produced diversity of polypeptide constructs for a polypeptide construct having said one or more desired characteristics. The present invention further relates to polypeptide constructs directed against one or more antigens and/or epitopes having one or more desired characteristics, wherein the polypeptide construct comprises at least two single domain antibodies. The methods and polypeptide constructs according to the present invention are useful for the identification of optimal therapeutic compounds. | 02-03-2011 |
20110028696 | MONOCLONAL ANTIBODIES AGAINST PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LACKING IN FUCOSYL RESIDUES - The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA | 02-03-2011 |
20110028697 | PROPHYLACTIC/THERAPEUTIC AGENT FOR INFECTIOUS DISEASE - Disclosed is a prophylactic or therapeutic agent for bacterial infectious diseases, which comprises an antibody capable of binding to a toxin or an antitoxin that constitutes a bacterial toxin-antitoxin system to inhibit the interaction between the toxin and the antitoxin or a gene for the antibody as an active ingredient. | 02-03-2011 |
20110034673 | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR - Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF. | 02-10-2011 |
20110034674 | Virus filtration methods - The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process. | 02-10-2011 |
20110034675 | Ilt3 Binding Molecules And Uses Therefor - The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). The binding molecules of the invention are characterized by binding to hILT3 with high affinity and downmodulating immune responses in vitro, e.g., downmodulating alloimmune responses; the production of inflammatory cytokines by dendritic cells, e.g., monocyte-derived dendritic cells (MDDC); the upregulation of costimulatory molecules by DC, e.g., MDDC; and/or calcium flux in monocytes. In addition, the binding molecules upregulate the expression of inhibitory receptors on dendritic cells, e.g., immature dendritic cells. Surprisingly, these same binding molecules which downmodulate immune responses in vitro, are immunostimulatory in vivo. | 02-10-2011 |
20110034676 | ANTI-SIALIC ACID ANTIBODY MOLECULES - A method of generating and isolating a recombinant high affinity anti-sialic acid antibody molecule comprises the steps of immunising a host with an immunogen comprising a conjugate of sialic acid and a carrier protein to generate an anti-sialic acid polyclonal serum, isolating a sample of RNA from the immunised avian host, and generating and screening of a library of recombinant antibody molecules from the RNA sample, and isolating a recombinant high affinity anti-sialic acid antibody molecule. The antibody molecule is selected from the group consisting of: whole antibodies; scFv fragments; and Fab fragments, and the host is | 02-10-2011 |
20110040074 | PRODUCTION METHODS - The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed. | 02-17-2011 |
20110040075 | ANTIBODY PURIFICATION BY PROTEIN A AND ION EXCHANGE CHROMATOGRAPHY - A novel method for selectively removing leaked protein A from antibody purified by means of protein A affinity chromatography is disclosed. | 02-17-2011 |
20110046354 | Humanized High Affinity Recombinant Antibody Against Hepatitis B Surface Antigen - This invention relates to a high affinity recombinant humanized antibody fragment (scFv) specific for hepatitis B surface antigen having unique inter/intra chain bonding interaction because of 28 altered amino acid residues from the original mouse (5S) antibody and its chimeric Fab form, wherein fine tuning of the vernier zone residue makes it closer to the human sequence without any structural constraints. | 02-24-2011 |
20110046355 | CYTOTOXIC IMMUNOGLOBULIN - The invention relates to a cytotoxic modular antibody with a molecular weight of up to 6 OkD, specifically binding to a cell surface target with a binding affinity of Kd<10 | 02-24-2011 |
20110054148 | ANTIBODIES TO INTERFERON-LIKE PROTEIN ZCYTO21(IL-29) - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 03-03-2011 |
20110065899 | ANTIBODY AGAINST RGD IN AMINO ACID SEQUENCE OF EXTRACELLULAR MATRIX PROTEIN AND PRODUCTION METHOD AND USE OF THE SAME - The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases. | 03-17-2011 |
20110065900 | SEPARATION METHOD UTILIZING POLYALLYLAMINE LIGANDS - The present invention relates to a method for removing at least one negatively charged substance from an aqueous liquid by contacting the liquid with a separation matrix comprising a plurality of polyallylamine ligands, comprising binding said negatively charged substance to said ligands under conditions where the ionic strength of the aqueous liquid applied to the chromatography resin ≧0.25 M NaCl. | 03-17-2011 |
20110071276 | Method of modifying a monoclonal antibody - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies. | 03-24-2011 |
20110077383 | HINGE DOMAIN ENGINEERING - The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which improves stability and/or alters the binding of Fc to one or more metal ion and/or one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that are less susceptible to metal ion-mediated cleavage and/or have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. Furthermore, the modified hinge of the Fc variants retains a similar flexibility to the wild type hinge. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes. | 03-31-2011 |
20110077384 | PROTEIN REFOLDING METHOD - The present invention provides a method for producing a protein which has a restored native higher-order structure by bringing a protein which has lost its native higher-order structure into contact at pH 6.5 to 9.0 with a 1 to 3% aqueous solution of a specific surfactant, such as lauroylglutamic acid to obtain a solubilized solution of the protein; and then adding the solubilized solution to a buffer with pH 6.5 to 9.0 containing arginine or an arginine derivative at a concentration of 0.1 to 1.2 M to lower the concentration of the specific surfactant, such as lauroylglutamic acid, in the obtained mixture solution down to 0.02 to 0.275%. According to the present invention, it is possible to easily restore the native higher-order structure of a protein while smoothly removing the surfactant from the protein. | 03-31-2011 |
20110087010 | ANTI-ANGIOGENIC COMPOUNDS - The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis. | 04-14-2011 |
20110098449 | MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR - The invention provides methods and compositions for modulating hepatocyte growth factor activator function. | 04-28-2011 |
20110105726 | ANTIBODIES TO HSDEK49 POLYPEPTIDES - The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating immune disorders and diseases. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention. | 05-05-2011 |
20110105727 | Method for the humanization of antibodies and humanized antibodies thereby obtained - Method for the humanization of the VII and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies. | 05-05-2011 |
20110105728 | METHOD FOR THE HUMANIZATION OF ANTIBODIES AND HUMANIZED ANTIBODIES THEREBY OBTAINED - Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies. | 05-05-2011 |
20110105729 | BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications. | 05-05-2011 |
20110105730 | AFFINITY CHROMATOGRAPHY MATRICES AND METHODS OF MAKING AND USING THE SAME - The invention provides methods of coupling protein ligands to a solid support. The invention also provides affinity chromatography matrices and methods of using affinity chromatography matrices to purify a target molecule. | 05-05-2011 |
20110105731 | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon - Provided herein are antibodies, fragments and derivatives of an antibody containing a binding domain thereof, where the antibody, fragment or derivative specifically binds to a single chain protease domain of a type II transmembrane serine protease (MTSP). Methods using the antibodies to modulate the protease activity of an MTSP are provided. Also provided are antibodies that bind to MTSPs designated MTSP3 and MTSP4 and to a form of an MTSP designated MTSP6. | 05-05-2011 |
20110112279 | Compositions and Methods Relating to STOP-1 - The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein. | 05-12-2011 |
20110118443 | ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES - Methods for designing optimized antibodies, including optimized humanized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them. | 05-19-2011 |
20110118444 | BINDING MOLECULES - The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. | 05-19-2011 |
20110130546 | IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS - The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided. | 06-02-2011 |
20110137014 | SUPER HUMANIZED ANTIBODIES - Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences. Top ranking human sequences are selected to provide the framework sequences for constructing a chimeric antibody that functionally replaces human CDR sequences with the non-human CDR counterparts using the selected subset member human frameworks, thereby providing a humanized antibody of high affinity and low immunogenicity without need for comparing framework sequences between the non-human and human antibodies. Chimeric antibodies made according to the method are also disclosed. | 06-09-2011 |
20110137015 | Markers of XMRV Infection and Uses Thereof - The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. Additionally, the invention relates to specific XMRV antigens capable of inducing an immunogenic response as well as XMRV-related nucleic acids having significant diagnostic, screening, and therapeutic utilities. | 06-09-2011 |
20110137016 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 06-09-2011 |
20110137017 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES - Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: | 06-09-2011 |
20110144308 | COMPOSITIONS AND METHODS FOR HUMANIZATION AND OPTIMIZATION OF N-GLYCANS IN PLANTS - Methods for altering the N-glycosylation pattern of proteins in higher plants are provided. The methods comprise introducing into the plant a recombinant construct that provides for the inhibition of expression of α1,3-fucosyltransferase (FucT) and β1,2-xylosyltransferase (XylT) in a plant. Use of these constructs to inhibit or suppress expression of both of these enzymes, and isoforms thereof, advantageously provides for the production of endogenous and heterologous proteins having a “humanized” N-glycosylation pattern without impacting plant growth and development. Stably transformed higher plants having this protein N-glycosylation pattern are provided. Glycoprotein compositions, including monoclonal antibody compositions, having substantially homogeneous glycosylation profiles, and which are substantially homogeneous for the G0 glycoform, are also provided. | 06-16-2011 |
20110152504 | CD16A Binding Proteins and Use for the Treatment of Immune Disorders - CD 16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia. | 06-23-2011 |
20110152505 | METHOD FOR DECREASING IMMUNOGENICITY - A method for decreasing the immunogenicity of antibody variable domains is disclosed. | 06-23-2011 |
20110160437 | METHODS OF PURIFYING ANTI A BETA ANTIBODIES - The present application provides methods of purifying Aβ binding proteins having a Fc region, for example, anti-Aβ antibodies or antibody fusions, by adsorbing the Aβ binding protein to a Fc binding agent, such as, for example, Protein A or Protein G, followed by a wash with a divalent cation salt buffer to remove impurities and subsequent recovery of the adsorbed Aβ binding protein. The present application also features methods of eluting the purified Aβ binding protein as well as the incorporation of the methods within a purification train. Kits comprising components for carrying out the methods and instructions for use are also provided. | 06-30-2011 |
20110160438 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF - The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides. | 06-30-2011 |
20110160439 | Design of specific ligands to sortilin - The present invention provides a Sortilin crystal and methods for growing said crystal. The invention furthermore provide methods for design of specific ligands based on the crystal structure of Sortilin. The present invention also relates to the preparation and use of such ligands for the preparation of a medicament for the treatment of disease, damage or disorders of the central and peripheral nervous systems. | 06-30-2011 |
20110166329 | Combinations of SAP depleting agents and anti-SAP antibodies - The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component. | 07-07-2011 |
20110166330 | GPCR crystalization method using an antibody - An antibody that specifically binds a three dimensional epitope on the IC3 loop of a GPCR is provided. The antibody may be employed in a method that comprises: contacting a GPCR with a monovalent version of the antibody binding conditions to form a complex; and crystallizing the complex. | 07-07-2011 |
20110166331 | IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS - The present invention relates to IL-17 Receptor A antigen binding proteins, such as antibodies, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation. | 07-07-2011 |
20110172397 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 07-14-2011 |
20110172398 | BISPECIFIC BINDING MOLECULES FOR ANTI-ANGIOGENESIS THERAPY - Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a Dll4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and Dll4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same. | 07-14-2011 |
20110172399 | IL-21 ANTAGONISTS - Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases. | 07-14-2011 |
20110178278 | Antibody Against the CSF-1R - The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions. | 07-21-2011 |
20110184151 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREFOR - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation. It further relates to protocols for screening for agents that modulate the Epidermal Growth Factor Receptor, and the agents resulting from said screening. The invention further a method for delivering therapeutic molecules to the interior of cells. | 07-28-2011 |
20110184152 | Biological Products - A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab′ fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween. | 07-28-2011 |
20110190477 | Humanized Anti-C5aR Antibodies - The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor. | 08-04-2011 |
20110190478 | Purification Process for Fragment Antibodies - A process for purification of a fragment antibody from a culture medium also comprising at least one impurity is provided. The purification is carried out after the pH of the culture medium has been reduced to a pH at which the fragment antibody is soluble, but one or more of the impurities are insoluble. A process for the preparation of a fragment antibody employing such a purification process is also provided. | 08-04-2011 |
20110207917 | SAM-6 VARIANTS, TARGET AND METHODS OF USE - The invention provides polypeptide, nucleic acid and other compositions. Polypeptide, nucleic acid and other compositions are useful in treatment and diagnostic methods. One treatment method includes inhibiting growth or proliferation of hyperproliferative cells or inducing regression of hyperproliferative cells, such as cells of a cellular hyperproliferative disorder, or reducing levels of LDL or oxLDL. | 08-25-2011 |
20110213127 | METHODS FOR USING AND IDENTIFYING MODULATORS OF DELTA-LIKE 4 - In certain embodiments, this present invention provides antibodies that act as either agonists or antagonists of Delta-like 4 (Dll4) signaling. | 09-01-2011 |
20110218328 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS - Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease. | 09-08-2011 |
20110218329 | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 09-08-2011 |
20110224408 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS - Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease. | 09-15-2011 |
20110230646 | HYBRID ANTIBODIES - Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments 5 contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and 10 nonhuman CDRs. | 09-22-2011 |
20110237779 | CDR-REPAIRED ANTIBODIES - The present application concerns restoring antigen binding during humanization of antibodies through the selection of repaired hypervariable regions rather than through framework changes. | 09-29-2011 |
20110237780 | ANTI-INFLAMMATORY DAB - The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-α, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate. | 09-29-2011 |
20110245469 | INTERMEDIATES FORMED IN BIOSYNTHESIS OF RELAXIN-FUSION PROTEINS WITH EXTENDED IN VIVO HALF-LIVES - Disclosed are human relaxin-Fc fusion proteins having an increased serum half-life, polynucleotides encoding the same, and intermediates formed during the fusion protein biosynthesis. The fusion proteins may include a linker portion or other sections as well. Suitable fusion proteins are also those predicted to have the same effect as human relaxin in vivo, based, for example, on structural modeling. The fusion protein is useful in the treatment of a number of diseases and conditions, including heart disease, vascular disease, wound healing, fibrosis, fibromyalgia, and promoting angiogenesis. | 10-06-2011 |
20110251374 | ANTIBODY PURIFICATION METHOD - Provided is a purification method that purifies an antibody to a high purity, effectively removes antibody polymer (or aggregate), and improves antibody recovery rate. An antibody purification method including a step for treating a solution containing an antibody by mixed mode chromatography in the presence of an amino acid is provided. | 10-13-2011 |
20110251375 | SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS - Immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind, obtained from display libraries. | 10-13-2011 |
20110257371 | Methods of Treating Chronic Pain - Methods of Treating Chronic Pain The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody. | 10-20-2011 |
20110257372 | IMMUNOGLOBULINS DEVOID OF LIGHT CHAINS - There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains. | 10-20-2011 |
20110263825 | ANTI-CD20 MONOCLONAL ANTIBODIES - It is intended to provide a monoclonal antibody having a growth inhibitory activity against a cell having a human CD20 antigen which is produced by using, as immunogens, a human B cell line expressing the human CD20 antigen and a cell line originating in a non-human animal, which is different from an animal to be immunized and has been transformed with human CD20 DNA, and a monoclonal antibody obtained by chimerization or humanization of the above-described monoclonal antibody. These monoclonal antibodies show biological activities suitable for using as drugs. | 10-27-2011 |
20110263826 | ANTIBODIES WHICH BIND SELECTIVELY TO HAIR OF ANIMALS AND AN ANTIBODY BASED DRUG DELIVERY SYSTEM FOR ANIMALS - The present invention provides antibodies which bind selectively to hair of animals and an antibody based drug delivery system in which a particular formulation can be directed to animal hair. This is driven by the need of increasing the effective period of therapeutics for animal ectoparasites treatment, reducing the toxicity of these drugs and improving their release profile | 10-27-2011 |
20110263827 | Dual Variable Domain Immunnoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 10-27-2011 |
20110263828 | METHODS FOR MODIFYING HUMAN ANTIBODIES BY GLYCAN ENGINEERING - Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided. | 10-27-2011 |
20110263829 | CELL-PENETRATING, SEQUENCE-SPECIFIC AND NUCLEIC ACID-HYDROLYZING ANTIBODY, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are a cell-penetrating, base sequence-specific, nucleic acid-hydrolyzing antibody, a method of preparing the same, and a pharmaceutical composition comprising the same. The antibody can be prepared by modifying a particular site of a cell-penetrating, nucleic acid-hydrolyzing antibody which lacks substrate specificity to impart sequence specificity thereto without alteration in nucleic acid-hydrolyzing ability. The antibody, when penetrating into cells by itself or ectopically expressed within cells, binds specifically to single- or double-stranded nucleic acid targets and hydrolyzes them, thus downregulating the expression of the targeted genes. | 10-27-2011 |
20110263830 | PROCESS FOR THE MODULATION OF THE ANTAGONISTIC ACTIVITY OF A MONOCLONAL ANTIBODY - The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, the antibody being capable of inhibiting one or more of the biological activities of the target molecule, wherein the process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of the hinge region by the deletion, the addition or the substitution of at least one amino acid. The disclosure also relates to polypeptides useful for such a modulation method and the obtained antibodies | 10-27-2011 |
20110282033 | AMINO ACID SEQUENCES DIRECTED AGAINST GROWTH FACTOR RECEPTORS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH GROWTH FACTORS AND THEIR RECEPTORS - The present invention relates to amino acid sequences that are directed against receptors for growth factors, compounds comprising such sequences, as well as nucleic acid sequences encoding the same. In one embodiment the invention relates to amino acid sequences that bind to a receptor tyrosine kinase. The receptor tyrosine kinase and/or growth factor receptor may be of human origin. In one embodiment the amino acid sequences are Nanobodies™. | 11-17-2011 |
20110282034 | PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS - The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists. | 11-17-2011 |
20110288276 | CRYSTALS AND STRUCTURE OF A HUMAN IgG Fc VARIANT WITH ENHANCED FcRn BINDING - Provided herein are crystalline forms of a human IgG Fc variant comprising triple-mutation M252Y/S254T/T256E that provides for increased binding affinity to human neonatal Fc receptor, methods of obtaining such crystals and high-resolution X-ray diffraction structures and atomic structure coordinates. Also provided are machine readable media embedded with the three-dimensional atomic structure coordinates of the human IgG Fc variant and methods of using them. | 11-24-2011 |
20110294984 | Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity - The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity. | 12-01-2011 |
20110301331 | Stabilized polypeptide compositions - The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules. | 12-08-2011 |
20110301332 | ANTI-PAMP THERAPEUTIC ANTIBODIES - The invention relates to antibodies and antigen-binding fragments thereof which bind to proadrenomedullin N-terminal peptide (“PAMP”). Furthermore, the invention comprises monoclonal antibody EGX-P-E9 as well as engineered variants thereof, including chimeric, humanized or de-immunized versions thereof. The antibodies of the invention are useful for inhibiting the physiological activities of PAMP as well as in diagnosis of PAMP-responsive conditions. | 12-08-2011 |
20110301333 | REMOVAL OF PROTEIN AGGREGATES FROM BIOPHARMACEUTICAL PREPARATIONS USING CALCIUM PHOSPHATE SALTS - The present invention provides novel and improved compositions containing calcium phosphate and methods of using the same for the removal of protein aggregates from biopharmaceutical compositions containing a product of interest, e.g., a therapeutic antibody or protein. | 12-08-2011 |
20110301334 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES - Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support. | 12-08-2011 |
20110301335 | ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS - The invention relates to anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient. | 12-08-2011 |
20110306756 | Prevention and Treatment of Amyloidogenic Disease - The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide, active fragments thereof or an antibody thereto. | 12-15-2011 |
20110313134 | ENGINEERED ANTIBODIES WITH REDUCED IMMUNOGENICITY AND METHODS OF MAKING - Hybrid antibodies and antibody binding fragments thereof having decreased immunogenicity and methods of making them are provided. The methods involve replacing one or more amino acid residues within at least one donor framework region of a hybrid antibody or antigen binding fragment thereof that has undergone somatic hypermutation with the amino acid residue from the corresponding position of a germline framework sequence. Also provided are hybrid antibodies or antigen binding fragments thereof containing at least two donor framework regions that are derived from the same germline gene family or germline gene family member and wherein at least one amino acid residue within a framework region has been replaced with an amino acid residue from the corresponding position within a germline framework region. The hybrid antibodies or antigen binding fragments thereof may contain human framework regions and nonhuman CDRs. | 12-22-2011 |
20110313135 | Recombinant Monovalent Antibodies - The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required. | 12-22-2011 |
20110313136 | IgG-Fc FRAGMENT AND PROCESS FOR PRODUCING THE SAME - A full-length IgG-Fc fragment having a substantially homogeneous sugar chain added thereto, and a process for producing the full-length IgG-Fc fragment. Specifically, an IgG-Fc fragment has a sugar chain added thereto, in which the sugar chain is added to the same position as that in a naturally occurring IgG-Fc fragment, any one amino acid residue selected from 1st to 30th amino acid residues from the sugar chain-added amino acid residue on the N-terminal side of the sugar chain-added amino acid residue is substituted by a Cys residue and at least one Met reside is substituted by an amino acid reside other than a Met residue. | 12-22-2011 |
20110313137 | HER2 ANTIBODY COMPOSITIONS - The invention relates to compositions of Her2 antibody molecules with pre-selected N-linked glycosylation forms. | 12-22-2011 |
20110313138 | Method for Producing Proteins - This invention provides a method for obtaining a recombinant antibody with a desired function, comprising: (a) providing a population of antibody-forming cells suspected of containing at least one cell capable of producing an antibody exhibiting the desired function; (b) generating one or more transcriptionally active recombinant linear polynucleotides from the antibody forming cells obtained in step (a) wherein each transcriptionally active recombinant linear polynucleotide comprises a polynucleotide sequence encoding a variable domain of an antibody produced by an antibody-forming cell obtained in step (a) and one or more transcription regulatory elements; (c) expressing a recombinant antibody using one or more of the transcriptionally active recombinant linear polynucleotides generated in step (b); (d) screening the recombinant antibody produced by step (c) for the desired function; and (e) optionally repeating steps (b), (c) and (d) to identify a recombinant antibody exhibiting the desired function. | 12-22-2011 |
20110319597 | VARIANT DOMAIN ANTIBODIES - The present invention relates to domain antibodies which have modified framework regions such that the potency or level of binding of the domain antibody is improved. In particular the present invention relates to domain antibodies which bind TNFa in which changes have been made to framework sequences and to constructs including these domain antibodies. | 12-29-2011 |
20110319598 | METHODS AND MATERIALS FOR DETERMINING ISOELECTRIC POINT - The present disclosure relates to methods and materials for determining an isoelectric point for a protein including, for example, a binding molecule such as an antibody. The isoelectric points may be used in methods for the preparation of proteins. Such methods may comprise identifying amino acid residues that are exposed on the surface of the protein in a sequence of amino acid residues of the protein, assigning a pKa value to the surface exposed amino acid residues, and calculating the isoelectric point of the protein from the pKa values assigned to the surface exposed amino acid residues. The methods of the present disclosure may be used for selecting and utilizing a buffer for purification of a protein, preparing a protein formulation, purifying a protein and/or stabilizing a protein in solution. | 12-29-2011 |
20120010387 | ANTIBODY VARIANTS COMPOSITION - Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required. The present invention provides an antibody variant composition, comprising amino acid residues of an Asn-X-Ser/Thr (X represents an amino acid residue other than Pro) sequence at positions other than positions 297 to 299 according to the EU index in an Fc region of a human IgG antibody, in which at least one amino acid substitution selected from an amino acid substitution of Asn to other amino acid residue, an amino acid substitution of X to Pro and an amino acid substitution of Ser/Thr to other amino acid residue is carried out, and a fragment of the antibody variant composition. | 01-12-2012 |
20120010388 | LeY SPECIFIC BIOTHERAPEUTIC - Embodiments are related to the field of immunology, and provide a highly avid LeY specific biotherapeutic including at least one further binding site having a different specificity to bind an epitope of a glycosylated cell surface molecule of a tumor cell, characterized by EC50 of less than 1 mM to confer immediate cytotoxicity to the tumor cell. | 01-12-2012 |
20120016107 | GROWTH FACTOR HTTER36 - The present invention discloses Growth Factor HTTER36 (GDF3) polypeptides and polynucleotides encoding such polypeptides. Also provided are antibodies that bind HTTER36, including chimeric, humanized, and single chain antibodies. | 01-19-2012 |
20120016108 | COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASE - The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage. | 01-19-2012 |
20120022236 | Recombinant Anti-VLA4 Antibody Molecules - The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation. | 01-26-2012 |
20120022237 | PEPTIDES FOR TREATMENT AND DIAGNOSIS OF BONE DISEASES - The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide. | 01-26-2012 |
20120022238 | EFFECTOR FUNCTION ENHANCED RECOMBINANT ANTIBODY COMPOSITION - Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient. | 01-26-2012 |
20120029172 | Humanized GM-CSF antibodies - Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as methods for manufacturing these, are also disclosed. | 02-02-2012 |
20120035350 | POLYNUCLEOTIDE ENCODING A NOVEL HUMAN P2X7 SPLICE VARIANT, HBMYP2X7V - The present invention provides novel polynucleotides encoding HBMYP2X7v polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HBMYP2X7v polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 02-09-2012 |
20120041181 | FUSION PROTEINS FORMING TRIMERS - The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein. | 02-16-2012 |
20120046450 | Modulation Of Antibody Effector Function By Hinge Domain Engineering - The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes. | 02-23-2012 |
20120046451 | ANTI-lgSF4 ANTIBODY AND UTILIZATION OF THE SAME - It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc. | 02-23-2012 |
20120059154 | ANTIGEN BINDING POLYPEPTIDES - The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae. | 03-08-2012 |
20120059155 | Method of Controlling O-Linked Glycosylation of Antibodies - A method for producing antibodies in fungal host cells is provided where the produced antibodies has a low degree of glycosylation. | 03-08-2012 |
20120059156 | METHOD OF PROTEIN NANOSTRUCTURE FABRICATION - A method of assembling a protein nanostructure on a surface including selectively patterning a surface with a fixation site, bringing a protein node into contact with the surface, and allowing the protein node to bond with the fixation site, so that the position and/or orientation of the protein node is constrained, and compositions. | 03-08-2012 |
20120065379 | Antibody Constant Region Variant - By means of amino acid sequence alterations, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated. | 03-15-2012 |
20120065380 | DUAL TARGETING ANTIBODY OF NOVEL FORM, AND USE THEREOF - The present invention relates to: a dual targeting antibody of a novel form having a water-soluble ligand fused to the N-terminus of a heavy chain or light chain of an antibody; a DNA encoding the dual targeting antibody; a recombinant expression vector containing the DNA; a host cell which is transformed with the recombinant expression vector; a method for preparing the dual targeting antibody by culturing the host cell; and a pharmaceutical composition including the dual targeting antibody. | 03-15-2012 |
20120071634 | Antibody Constant Region Variant - By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region. | 03-22-2012 |
20120077962 | HUMANIZED ANTI-PROSTATE STEM CELL ANTIGEN MONOCLONAL ANTIBODY - Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA. | 03-29-2012 |
20120083588 | Neutral amino acid transporter and gene thereof - The present invention relates to an amino acid transporter protein having the ability to mediate the transport of amino acids into a cell, a gene encoding the protein, an antibody having a reactivity with the protein, a cell which produces the antibody, related kits and methods. | 04-05-2012 |
20120083589 | Antibody Modulating The Differentiation And Function Of Dendritic Cells Via Binding Intercellular Adhesion Molecule-1 And Use Thereof - The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease. | 04-05-2012 |
20120088905 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index. | 04-12-2012 |
20120095191 | LH-TYPE BISPECIFIC ANTIBODY - Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (LH-diabody type bispecific antibody) characterized in that an L-chain is located in the N-terminal side in each polypeptide (LH type); a humanized high-functional bispecific antibody which contains said LH diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule. | 04-19-2012 |
20120095192 | USE OF TRIFUNCTIONAL BISPECIFIC ANTIBODIES FOR THE TREATMENT OF TUMORS ASSOCIATED WITH THE CD133+/EPCAM+ CANCER STEM CELLS - Use of a trifunctional bispecific antibody having the following properties of a) binding to a T cell; b) binding to EpCAM as tumor-associated antigen on a tumor cell wherein the tumor cell additionally carries the membrane bound glycoprotein CD 133; c) binding by its Fc portion to Fc receptor-positive cells for the preparation of a pharmaceutical composition for the destruction of cancer stem cells carrying the tumor-associated antigen EpCAM and the membrane bound glycoprotein CD 133 in a population of patients suffering from a tumor. | 04-19-2012 |
20120095193 | POLYPEPTIDES AND METHOD OF TREATMENT - Provided herein are isolated antigen binding protein comprising at least one first immunoglobulin variable domain capable of binding to human ADAMTS5. Also provided are antigen binding proteins of the present invention that are monoclonal antibodies, pharmaceutical compositions comprising said antigen binding proteins and methods of treatment. | 04-19-2012 |
20120101260 | SUSTAINED DRUG DELIVERY SYSTEM - A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components. | 04-26-2012 |
20120101261 | USE OF MULTI-KINASE INHIBITORS IN THE TREATMENT OF VASCULAR HYPERPERMEABILITY - A multi-kinase inhibitor, in particular Sorafenib, is used for the preparation of a pharmaceutical composition in the treatment of a variety of pathological conditions involving vascular hyperpermeability in order to reduce vascular hyperpermeability. | 04-26-2012 |
20120101262 | PROTEIN PURIFICATION BY CAPRYLIC ACID (OCTANOIC ACID) PRECIPITATION - The invention provides methods for a purifying protein of interest from a mixture comprising the protein of interest and one or more contaminants, including host cell DNA and proteins, by precipitation of the contaminants with caprylic acid. Such methods are particularly useful for purifying antibodies from cell cultures. Moreover, mixtures that have been depleted of contaminants using the methods of the invention can be used directly in downstream chromatography applications (e.g., ion exchange chromatography) without any further purification. These methods lead to manufacturing processes with a minimum number of unit operations and reduce the resource requirements, and thus positively influence the cost of goods for therapeutic protein production. | 04-26-2012 |
20120116056 | Fc fusion proteins of human growth hormone - Fc fusion proteins of human growth hormone with good biological activities relative to rhGH on a molar basis are disclosed. The hGH-L-vFc fusion protein comprises hGH, a flexible peptide linker of about 20 or fewer amino acids, and a human IgG Fc variant. The Fc variant is of a non-lytic nature and shows minimal undesirable Fc-mediated side effects. A method is also disclosed to make or produce such fusion proteins at high expression levels. Such hGH-L-vFc fusion proteins exhibit extended or prolonged serum half-life and/or good biological activities relative to that of rhGH on a molar basis, leading to improved pharmacokinetics and pharmacodynamics, thus fewer injections will be needed within a period of time. | 05-10-2012 |
20120116057 | DESIGN OF STABLE AND AGGREGATION FREE ANTIBODY FC MOLECULES THROUGH CH3 DOMAIN INTERFACE ENGINEERING - The present invention relates to methods of increasing stability and reducing aggregation in compositions comprising antibody Fc molecules and to composition comprising such molecules. Certain amino acid substitutions in the CH3 domain result in increased stability and reduced aggregation of compositions containing polypeptides comprising a CH3 domain, e.g., an antibody or Fc-fusion protein. | 05-10-2012 |
20120123098 | Constructs and libraries comprising antibody surrogate light chain sequences - The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same. | 05-17-2012 |
20120123099 | AUTOANTIBODY PRODUCTION INHIBITOR - The present invention provides an autoantibody production inhibitor which can specifically suppress the autoantibodies and which can effectively prevent or treat the autoimmune disease of autoantibody type. According to the present invention, there is provided an autoantibody production inhibitor comprising, as an effective ingredient, a fusion protein which consists of a protein (X) containing a site recognized by autoantibodies which are a cause of the autoimmune disease of autoantibody type and a protein (A) containing a fragment which exhibits the antibody-dependent cellular cytotoxicity of the antibody heavy chain constant region. | 05-17-2012 |
20120142899 | NOVEL ANTI-NOTCH3 ANTIBODIES AND THEIR USE IN THE DETECTION AND DIAGNOSIS OF DISEASE - The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis. | 06-07-2012 |
20120142900 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention relates to anti-IL-6 antibodies and antibody fragments having a particular epitopic specificity. These antibodies and antibody fragments have clinical therapeutic and diagnostic applications in treating and detecting disease conditions wherein Il-6 levels are elevated. | 06-07-2012 |
20120142901 | PURIFICATION METHOD WHICH PREVENTS DENATURATION OF AN ANTIBODY - The present invention provides a method of purifying an antibody by protein A affinity chromatography. More specifically, the present invention provides a technique relating to an elution buffer solution which provides a good antibody recovery rate without denaturation. | 06-07-2012 |
20120142902 | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease - The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease. | 06-07-2012 |
20120149875 | AFFINITY CHROMATOGRAPHY MATRIX - The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the adsorbed immunoglobulin containing proteins; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins. The method improves upon previous separation methods being that each of the ligands consists essentially of a monomer or dimer SpA or protein Z or a functional variant thereof. | 06-14-2012 |
20120149876 | Stable Heterodimeric Antibody Design with Mutations in the Fc Domain - The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics. | 06-14-2012 |
20120149877 | TUMOR-SPECIFIC RECOGNITION MOLECULES - The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases. | 06-14-2012 |
20120149878 | PROTEIN PURIFICATION - Methods of reducing high molecular weight species (HMW) formation in a sample containing a protein purified using ion exchange (IEX) chromatography are disclosed, as are a number of related methods, e.g., methods of reducing on-column denaturation of a protein in a protein sample purified using an ion exchange (IEX) column or resin. The methods share characteristics of including arginine, glycine and/or histidine in the buffers used during the ion exchange (IEX) chromatography. | 06-14-2012 |
20120149879 | BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIES - The present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies. | 06-14-2012 |
20120149880 | Nucleic Acid Cassette For Producing Recombinant Antibodies - The invention provides a nucleic acid cassette comprising components in the following structure: A-B-C, wherein “A” is a nucleic acid sequence encoding a light chain of a first antibody (or antigen binding domain thereof), “B” is a nucleic acid sequence encoding a 2A peptide, “C” is a nucleic acid sequence encoding a heavy chain of a second antibody (or antigen binding domain thereof), and “-” is a phosphodiester or phosphorothioate bond. Also provided is a nucleic acid cassette with the structure A-p-B-C, where “p” is a nucleic acid encoding a protease recognition site, Also provided are methods for making recombinant antibodies using the nucleic acid cassette of the invention, cells and vector comprising the nucleic acid cassette of the invention, and kits for making the nucleic acid cassette of the invention. | 06-14-2012 |
20120157664 | METHOD FOR THE PRODUCTION OF DOMAIN ANTIBODIES - The present disclosure relates to a method for producing a domain antibody in a host other than | 06-21-2012 |
20120157665 | GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS - The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals. | 06-21-2012 |
20120157666 | INTERFERON-LIKE PROTEINS AND USES THEREOF - The present invention provides Interferon-Like (IFN-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IFN-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides. | 06-21-2012 |
20120165511 | PROTEIN PURIFICATION USING HCIC AND ION EXCHANGE CHROMATOGRAPHY - The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step. | 06-28-2012 |
20120172578 | FUNCTIONAL HEAVY CHAIN ANTIBODIES, FRAGMENTS THEREOF, LIBRARY THEREOF AND METHODS OF PRODUCTION THEREOF - The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, said positions determined according to the Kabat numbering. | 07-05-2012 |
20120178910 | CATION EXCHANGE CHROMATOGRAPHY (METHODS) - The present invention provides improved methods of protein purification using CEX chromatography. Such methods generally comprise the steps of: contacting a protein of interest (e.g., an antibody) with a cation exchange resin at a first pH, that is less than the pI of the most acidic isoform of the protein of interest, such that the protein of interest binds to the resin; washing the cation exchange resin at a second pH that is greater than the first pH, but less than the pI of the most acidic isoform of the protein of interest; and eluting the protein of interest from the resin at a third pH that is about equal to or less than the first pH. The methods of the invention are particularly useful for the commercial purification of recombinant therapeutic proteins (e.g., antibodies). | 07-12-2012 |
20120184716 | Methods for the Generation of Multispecific and Multivalent Antibodies - The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other of a Lambda constant domain. The invention provides methods for the isolation of antibodies of different specificities but sharing a common heavy chain. The invention also provides methods for the controlled co-expression of two light chains and a single heavy chain leading to the assembly of monospecific and bispecific antibodies. The invention provides a mean of producing a fully human bispecific and bivalent antibody that is unaltered in sequence and does not involve the use of linkers or other non-human sequences, as well as antibody mixtures of two monospecific antibodies and one bispecific antibody. The invention also provides the means of efficiently purifying the bispecific antibody. | 07-19-2012 |
20120184717 | ANTIBODIES AGAINST EXTENDED TYPE 1 CHAIN ANTIGENS, DERIVATIVES THEREOF AND USE - Disclosed herein are antibodies or antigen-binding portions thereof directed against extended Type I chain antigens, in particular extended Type I chain glycosphingolipids, and the uses of the antibodies or antigen-binding portions thereof in the diagnosis, amelioration, treatment or prevention of diseases or disorders in mammals, including humans, resulting from or associated with the improper activity/metabolism or the presence of extended Type I chain antigens, in particular extended Type I chain glycosphingolipids. | 07-19-2012 |
20120184718 | BISPECIFIC DEATH RECEPTOR AGONISTIC ANTIBODIES - The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 07-19-2012 |
20120190826 | NOVEL ANTIBIOTIC COMPRISING AN ANTIBODY MIMETIC, ITS PREPARATION METHODS AND USES THEREOF - The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic comprising an antibody mimetic antibody, its preparation methods and uses thereof. A novel antibiotic comprising a antibody mimetic covalently bonded to the carboxyl end of a colicin polypeptide or a channel-forming domain polypeptide of a colicin, wherein said colicin is selected from the group consisting of Colicin E1, Ia, Ib, A, B, N; wherein said antibody mimetic being yielded by fusing two complementarity determining regions (CDRs), V | 07-26-2012 |
20120190827 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses - Modified human plasma polypeptides or Fc and uses thereof are provided. | 07-26-2012 |
20120190828 | BIFUNCTIONAL POLYPEPTIDES - A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part. | 07-26-2012 |
20120190829 | ANTIGEN BINDING PROTEINS CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN - The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders. | 07-26-2012 |
20120208983 | METHODS, DEVICES, KITS AND COMPOSITIONS FOR DETECTING WHIPWORM - Methods, devices, kits and compositions for detecting the presence or absence of whipworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of whipworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, roundworm, and heartworm. Confirmation of the presence or absence of whipworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated. | 08-16-2012 |
20120208984 | HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR - The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies. | 08-16-2012 |
20120214971 | NOVEL ANTI-IL13 ANTIBODIES AND USES THEREOF - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 08-23-2012 |
20120220758 | ANTIBODY HAVING ACTIVITY OF INHIBITING HEPATITIS C VIRUS (HCV) INFECTION AND USE THEREOF - An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so as to be able to inhibit the binding of hepatitis C virus to the surface of a host cell and to inhibit HCV infection, a humanized antibody thereof, and an inhibitory agent for infection with hepatitis C virus. | 08-30-2012 |
20120226023 | CYTOMEGALOVIRUS SURFACE PROTEIN COMPLEX FOR USE IN VACCINES AND AS A DRUG TARGET - Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection. | 09-06-2012 |
20120226024 | CORE FUCOSYLATED GLYCOPEPTIDES AND GLYCOPROTEINS: CHEMOENZYMATIC SYNTHESIS AND USES THEREOF - A chemoenzymatic method for the preparation of a core-fucoslyated glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of a fucosylated GlcNAc-protein and fucosylated GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of an endoglycosidase (ENGase) selected from Endo;F1, Endo-F2, Endo-F3, Endo-D and related glycosynthase mutants to transfer the oligosaccharide moiety to the acceptor and yield the structure defined core-fucosylated glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of fucosylated glycoprotein or fucosylated glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody to include a predetermined sugar chain to replace a heterogeneous sugar chain, are also described. | 09-06-2012 |
20120238728 | MULTIVALENT ANTIBODIES AND USES THEREFOR - The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies. | 09-20-2012 |
20120238729 | Modified Antibody Constant Regions - The present inventors successfully provided constant regions capable of enhancing the agonist activity of antibodies through amino acid sequence alterations. Specifically, agonist activity was found to be enhanced in antibodies having a constant region in which amino acids of the antibody heavy chain constant region are substituted or deleted, or antibodies having a constant region in which the hinge region amino acids are substituted. Use of such antibodies as pharmaceutical formulations can provide pharmaceutical formulations with improved performance. | 09-20-2012 |
20120245329 | HIGH PRESSURE REFOLDING OF MONOCLONAL ANTIBODY AGGREGATES - Methods for refolding antibodies, particularly monoclonal antibodies, from aggregated and/or denatured preparations by subjecting the antibody preparation to high hydrostatic pressure are provided. Refolded preparations of antibodies produced by the methods described herein are also provided. | 09-27-2012 |
20120245330 | NEUROPILIN ANTAGONISTS - Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications. | 09-27-2012 |
20120253017 | STEM CELL TARGETING - The present invention describes an antigen-binding construct comprising a first agent which binds to a stem cell specific marker molecule and a second agent which binds to a tissue specific marker molecule. In particular, the invention describes a construct wherein the tissue specific marker is a muscle specific marker molecule. Such a construct may be used in a pharmaceutical composition for use in muscle regeneration or heart disease. | 10-04-2012 |
20120259095 | MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP) | 10-11-2012 |
20120264917 | BIPARATOPIC PROTEIN CONSTRUCTS DIRECTED AGAINST IL-23 - Biparatopic protein constructs that are directed against IL-23, and in particular against the p19 subunit of IL-23. The constructs comprise at least a first binding domain or binding unit directed against a first defined epitope on p19 and at least a second binding domain or binding unit directed against a second defined epitope on p19 (or the p19/p40 interface). The binding domains or binding units may in particular be a domain antibody, a single domain antibody, a dAb or a Nanobody®. The constructs and pharmaceutical compositions comprising the same can be used for the prevention and/or treatment of diseases and disorders associated with IL-23 or IL-23 mediated signaling, such as inflammation and inflammatory disorders such as colitis, Crohn's disease and IBD, infectious diseases, psoriasis, cancer, autoimmune diseases, sarcoidosis, transplant rejection, cystic Fibrosis, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, viral infection, and common variable immunodeficiency. | 10-18-2012 |
20120264918 | PURIFICATION METHOD WHICH PREVENTS DENATURATION OF AN ANTIBODY - The present invention provides a method of purifying an antibody by protein A affinity chromatography. More specifically, the present invention provides a technique relating to an elution buffer solution which provides a good antibody recovery rate without denaturation. | 10-18-2012 |
20120277411 | SINGLE CHAIN ANTIBODIES FOR PHOTOSYNTHETIC MICROORGANISMS AND METHODS OF USE - A single chain antibody that binds algae is described. The single chain antibody for algae is used to capture algae onto bioactive films. The single chain antibody is also used in a chimeric construct having a substrate binding domain and a single chain antibody domain. Dimers, trimmers, and multimer constructs are also described that aid in collection of algae from liquid mixtures by causing flocculation of algae cells. | 11-01-2012 |
20120283414 | Monoclonal Antibodies for Ebola and Marburg Viruses - Described herein are a number of Ebola and Marburg monoclonal antibodies. | 11-08-2012 |
20120283415 | Multivalent Antibodies - The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains. | 11-08-2012 |
20120283416 | WASH SOLUTION AND METHOD FOR AFFINITY CHROMATOGRAPHY - The invention provides a washing method for affinity chromatography in which a wash solution comprising arginine, or an arginine derivative, and a nonbuffering salt, preferably at high pH, greater than 8.0, is effective in removing impurities, such as high molecular weight species and host cell proteins, while also increasing product concentration in the eluate and maintaining a high percent yield of recovered product. | 11-08-2012 |
20120283417 | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME - Polypeptides comprising at least a first and second Fc fragment of IgG that can be used to induce a stimulated cell to produce the anti-inflammatory cytokine Interleukin-10 and methods of using the same are disclosed herein. | 11-08-2012 |
20120283418 | COVALENT DISULFIDE-LINKED DIABODIES AND USES THEREOF - The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions. | 11-08-2012 |
20120296069 | LIQUID FORMULATIONS FOR LONG-ACTING ERYTHROPOIETIN CONJUGATE - Disclosed is a liquid formulation which allows long-acting EPO conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting EPO conjugates. | 11-22-2012 |
20120302737 | COILED COIL AND/OR TETHER CONTAINING PROTEIN COMPLEXES AND USES THEREOF - The invention provides engineered protein complexes constructed using a coiled coil and/or a tether and methods for making, using, and purifying such complexes, such as multispecific antibodies or other multispecific Fc containing complexes. | 11-29-2012 |
20120302738 | Recombinant antibody vector - A recombinant antibody vector for producing a single chain recombinant antibody comprises: (a) a contiguous nucleotide sequence: (i) that comprises a restriction endonuclease site that encodes an amino acid sequence of an immunoglobulin variable region; and (ii) that encodes an immunoglobulin constant region amino acid sequence in the same reading frame as (i), wherein another nucleotide sequence encoding (iii) an immunoglobulin variable region amino acid sequence, is insertable into the restriction endonuclease site in the same reading frame as (ii); and (b) one or more regulatory nucleotide sequences operably linked or connected to said nucleotide sequence, wherein the amino acid sequence in (i) comprises amino acids conserved in different immunoglobulin variable regions. The restriction endonuclease site may be a SacI site which encodes the conserved amino acids glutamate and leucine. In frame insertion of the nucleotide sequence of (iii) is facilitated by ligase independent cloning. | 11-29-2012 |
20120302739 | BIOLOGICAL PRODUCTS - There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the clains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22. | 11-29-2012 |
20120309940 | GLYCOSYLATED REPEAT-MOTIF-MOLECULE CONJUGATES - Herein are reported glycosylated repeat-motif-molecule conjugate of the following formula: (repeat-motif-molecule−linker | 12-06-2012 |
20120309941 | IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases. | 12-06-2012 |
20120316324 | Disulfide Stabilised Multivalent Antibodies - A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest which are a VH/VL pair, wherein the two single domain antibodies are linked by a disulfide bond. Also provided are particular dual specificity antibody fusion proteins and other antibody fragments which are stabilised by a disulfide bond. | 12-13-2012 |
20120322982 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 12-20-2012 |
20120322983 | METHOD FOR PURIFYING PROTEIN - The present invention provides a method for purifying a protein to remove impurities from a mixture liquid containing a desired protein and the impurities, comprising performing filtration using a porous membrane having a graft chain on a pore surface and an anion-exchange group fixed to the graft chain. | 12-20-2012 |
20120322984 | METHODS OF REDUCING TRAIL-INDUCED APOPTOSIS BY TRAIL ISOFORMS - This document provides to methods and materials related to apoptosis. For example, methods and materials for modulating apoptosis are provided. In addition, methods and materials for treating a mammal having an apoptosis-associated condition are provided. | 12-20-2012 |
20120329994 | Production of a Monoclonal Antibody Therapeutic Against West Nile Virus in Plants - The present invention describes the plant-based production of a therapeutic antibody against West Nile Virus. | 12-27-2012 |
20120329995 | Novel Lowered Affinity Antibodies And Methods of Making the Same - The present invention provides methods for making novel, rationally designed lowered affinity antibodies. The methods of the present invention make antibodies that have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall (3) dimensional antibody structure. Using the antibodies made using methods of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects. | 12-27-2012 |
20120329996 | Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI) - Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided. | 12-27-2012 |
20120329997 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-27-2012 |
20130005949 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 01-03-2013 |
20130005950 | Stirred Tank Reactor And Method - Container for sample preparation or processing, such as biomass culturing or processing, and optionally sample purification. In certain embodiments, the reactor is a bioreactor that includes a stirred cell device that simulates a tangential flow filter to reduce or eliminate clogging that can be caused by the solids generated. In certain embodiments, the solids comprise a precipitate or floc or beads, such as one that includes a polymer that binds the biomolecule(s) of interest, and impurities. In its method aspects, embodiments disclosed herein include purification and isolation of biomolecules of interest derived from cell culture fluids. The methods include carrying out sample preparation or processing in a container, culturing a biomass; generating solids by precipitating or flocculating a biomolecule of interest from the cultured broth; preventing the solids from settling in the container by agitation; and purification, such as by eluting the biomolecule of interest and filtering the same. | 01-03-2013 |
20130018174 | POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERSAANM Igawa; TomoyukiAACI ShizuokaAACO JPAAGP Igawa; Tomoyuki Shizuoka JPAANM Sampei; ZenjiroAACI ShizuokaAACO JPAAGP Sampei; Zenjiro Shizuoka JPAANM Wakabayashi; TetsuyaAACI ShizuokaAACO JPAAGP Wakabayashi; Tetsuya Shizuoka JPAANM Ito; ErikoAACI ShizuokaAACO JPAAGP Ito; Eriko Shizuoka JP - The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies. | 01-17-2013 |
20130023651 | PEPTIDES FOR TREATMENT AND DIAGNOSIS OF BONE DISEASES - The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide. | 01-24-2013 |
20130023652 | HUMANIZATION OF RABBIT ANTIBODIES USING A UNIVERSAL ANTIBODY FRAMEWORK - The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications. | 01-24-2013 |
20130030155 | ANTIBODIES TO THE NOTCH1 RECEPTOR - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells. | 01-31-2013 |
20130030156 | ANTI-ILT5 ANTIBODIES AND ILT5-BINDING ANTIBODY FRAGMENTS - Disclosed herein are antibodies and ILT5-binding fragments thereof that specifically bind to ILT5, e.g., human ILT5 (hILT5), and pharmaceutical compositions comprising such ILT5-binding antibodies and ILT5-binding fragments thereof. | 01-31-2013 |
20130030157 | Rodent Combinatorial Antibody Libraries - The present invention provides synthetic rodent antibody libraries, such as mouse or rat antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries and variants of such antibodies. | 01-31-2013 |
20130035475 | Methods for Identifying Compounds That Modulate Ion Channel Activity of a Kir Channel - Methods for identifying compounds that modulate the ion channel activity of a Kir channel are provided. Methods for identifying compounds that selectively modulate the ion channel activity of specific types of Kir channels based on the turret region of a Kir channel are also provided. Methods for identifying compounds to treat conditions associated with abnormal ion channel activity are also provided. Compounds including purified antibodies and methods of making antibodies which bind to the turret region of a Kir channel are provided. Purified polypeptides including at least a portion of the turret region of a Kir channel and nucleic acid sequences encoding these polypeptides are also provided. | 02-07-2013 |
20130035476 | CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A IN COMPLEX WITH FIBRINOGEN DERIVED PEPTIDE AND USES THEREOF - The present invention discloses crystal structure of | 02-07-2013 |
20130041136 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 02-14-2013 |
20130046078 | ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME - The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies. | 02-21-2013 |
20130046079 | MOUSE LAMBDA LIGHT CHAIN LOCUS - The present invention provides in a first aspect a mouse in which the λ (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse λ light chain locus was functional silenced by deletion of acne segments coding for the λ light chain locus. In a further aspect, a mouse containing functionally silenced λ and κ (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies. | 02-21-2013 |
20130053548 | Protein A Crystals and Cross-Linked Crystals and Methods of Use Thereof - Protein A crystals and Protein A cross-linked protein crystals (CLPCs) are described. Methods of preparing and using are also disclosed. | 02-28-2013 |
20130053549 | Multivalent Antibodies - The present invention provides a recombinant antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a C | 02-28-2013 |
20130060010 | DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS - In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker. | 03-07-2013 |
20130060011 | FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE - The present invention relates to bispecific antibodies comprising at least two fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 03-07-2013 |
20130066051 | FUSION POLYPEPTIDE AGAINST EB VIRUS-INDUCED TUMOR AND COLICIN IA MUTANT - The present invention provides a fusion polypeptide against EB virus-induced tumor, which comprises an antibody or a mimetic antibody against EB virus and an ion channel forming colicin selected form E1, Ia, Ib, A, B, N and their mutants. The present invention also provides a colicin Ia mutant, which comprises mutations of G11A, H22G, A26G, V31L, and H40D. The present invention also provides a gene, vector, preparation method and use of the fusion polypeptide, and provides a gene and use of the mutant. | 03-14-2013 |
20130066052 | UCP4 - The present invention is directed to novel polypeptide, designated in the present application as “UCP4” (SEQ ID NO: 1), having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention. | 03-14-2013 |
20130072663 | Antibodies to Alpha Synuclein - The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals. | 03-21-2013 |
20130079500 | FUSION PROTEINS FOR TREATING METABOLIC DISORDERS - The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions. | 03-28-2013 |
20130090456 | METHODS FOR IDENTIFYING IMMUNOBINDERS OF CELL-SURFACE ANTIGENS - The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods. | 04-11-2013 |
20130096281 | METHODS AND COMPOSITIONS FOR DISPLAYING A POLYPEPTIDE ON A YEAST CELL SURFACE - Provided herein are methods and compositions for use in displaying a polypeptide (e.g., an antibody polypeptide or an antibody polypeptide fragment) on the surface of a yeast cell. Exemplary yeast that can be used in conjunction with various methods and compositions disclosed herein include those of the genus | 04-18-2013 |
20130096282 | THERAPEUTIC ANTIBODIES AGAINST FLAGELLATED PSEUDOMONAS AERUGINOSA - Improved antibodies are provided selected from human, dual-specific, chimeric or humanized antibodies, wherein said human chimeric and humanized antibodies specifically bind to flagellin type A or type B of | 04-18-2013 |
20130102762 | ANTI-PSGL-1 ANTIBODIES - Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject. | 04-25-2013 |
20130109839 | PROCESS FOR THE MODULATION OF THE ANTAGONISTIC ACTIVITY OF A MONOCLONAL ANTIBODY | 05-02-2013 |
20130109841 | ANTI-cMET ANTIBODY | 05-02-2013 |
20130109842 | AMINO ACID SEQUENCES OF NANOBODIES DIRECTED AGAINST P19 SUBUNIT OF THE HETERODIMERIC CYTOKINE IL-23 | 05-02-2013 |
20130109843 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | 05-02-2013 |
20130123471 | Antibody Against Carcinoembryonic Antigen and Uses Thereof - The invention discloses a humanized chimeric monoclonal antibody against carcinoembryonic antigen (CEA), polynucleotides encoding the antibody, expression vectors comprising the polynucleotides, and host cells containing the expression vectors. The invention also discloses uses of the antibody, polynucleotides, vectors and host cells for manufacturing medicaments for diagnosis and/or treatment of tumors. | 05-16-2013 |
20130131320 | HIGHLY-FUNCTIONAL MUTANT OF HUMANIZED ANTI-EGFR ANTIBODY VARIABLE REGION | 05-23-2013 |
20130131321 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY - The present invention relates to the use for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) | 05-23-2013 |
20130137855 | HUMANIZED ANTI-INTERLEUKIN 3 RECEPTOR ALPHA CHAIN ANTIBODIES - The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof. | 05-30-2013 |
20130137856 | PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF - The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases. | 05-30-2013 |
20130144040 | ANTAGONIST ANTI-NOTCH3 ANTIBODIES AND THEIR USE IN THE PREVENTION AND TREATMENT OF NOTCH3-RELATED DISEASES - The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders. | 06-06-2013 |
20130144041 | HOMOGENEOUS ANTIBODY POPULATIONS - The present invention is generally directed to methods of producing an increase in the enrichment and/or recovery of preferred forms of monoclonal antibodies. More particularly, the invention relates to methods for eliminating disulfide heterogeneity in the hinge region of recombinant IgG2 antibody proteins. | 06-06-2013 |
20130144042 | B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION - The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject. | 06-06-2013 |
20130150558 | DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS; APPLICATION TO ANTI-EGFR ANTIBODIES - In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof. | 06-13-2013 |
20130158237 | RECOMBINANT PROTEIN CAPABLE OF BINDING SPECIFICALLY AND QUICKLY TO TROPONIN I DERIVED FROM HUMAN MYOCARDIUM - Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65. | 06-20-2013 |
20130165638 | LIGHT CHAIN-BRIDGED BISPECIFIC ANTIBODY - This invention describes a novel format of monomeric bispecific fusion protein with immune activating property for clinical therapies. A bispecific fusion protein includes a first targeting domain with a specificity for a first target of interest; a bridging domain derived from a constant region of a light chain or heavy chain of an immunoglobulin, which may be a human immunoglobulin; and a second targeting domain with a specificity for a second target of interest. The bispecific fusion protein may further include a linker fused to the N-terminus or the C-terminus of the bridging domain. The first targeting domain is fused to the bridging domain and the second targeting domain is fused to the bridging domain or the linker. The linker may include a GGGGS sequence. The first target of interest may be CD | 06-27-2013 |
20130165639 | ACCEPTOR FRAMEWORK FOR CDR GRAFTING - The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications. | 06-27-2013 |
20130165640 | ACCEPTOR FRAMEWORK FOR CDR GRAFTING - The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications. | 06-27-2013 |
20130172533 | HUMANIZED ANTI-HUMAN CD34 MONOCLONAL ANTIBODY AND USES THEREOF - A novel humanized antibody against the CD34 surface antigen on the human stem cells is provided. The humanized antibody contains a heavy chain variable region comprising an amino sequence as set forth in SEQ ID No. 1 and a light chain variable region comprising an amino sequence as set forth in SEQ ID No. 2. The disclosure also provides the applications of the disclosed humanized antibody. | 07-04-2013 |
20130172534 | ANTIBODIES TO OX-2/CD200 AND USES THEREOF - This application provides methods and compositions for modulating and/or depleting CD200 positive cells. | 07-04-2013 |
20130178605 | Hetero-Dimeric Immunoglobulins - The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same. | 07-11-2013 |
20130178606 | RECOMBINANT PROTEIN CAPABLE OF BINDING SPECIFICALLY AND QUICKLY TO TROPONIN I DERIVED FROM HUMAN MYOCARDIUM - Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65. | 07-11-2013 |
20130178607 | PROCESS FOR PURIFYING PROTEINS - The present invention provides method for purifying a recombinant protein from a gram-negative bacterial host cell sample or extract thereof wherein said host cell expresses a recombinant protein and a recombinant disulphide isomerase DsbC; comprising: a. adjusting the pH of the host cell sample or extract thereof to a pH of 5 or less to precipitate the recombinant disulphide isomerase; and b. separating precipitated recombinant disulphide isomerase DsbC from the recombinant protein to produce a recombinant protein sample. | 07-11-2013 |
20130184439 | PROTEIN PURIFICATION - The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step. | 07-18-2013 |
20130184440 | SUPER-HUMANIZED ANTIBODIES - A method of preparing a germinalized hypervariable antibody region directed against a target, as well as the antibodies, antibody fragments, vectors and compositions including the germinalized hypervariable region. | 07-18-2013 |
20130197198 | Removal Of High Molecular Weight Aggregates Using Hydroxyapatite Chromatography - This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation. | 08-01-2013 |
20130197199 | ANTIBODY AGAINST HUMAN PROSTAGLANDIN E2 RECEPTOR EP4 - It is an object of the present invention to provide an antibody that binds to a human PGE | 08-01-2013 |
20130203963 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 08-08-2013 |
20130203964 | ANTIBODY DERIVATIVES - An anti-CEA scFv having an uncleaved Pel B leader sequence is surprisingly stable and is highly specific for CEA and CEACAM1. | 08-08-2013 |
20130203965 | Binding Agents - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 08-08-2013 |
20130203966 | NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS - The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma. | 08-08-2013 |
20130203967 | NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS - The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma. | 08-08-2013 |
20130211049 | IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF - The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be ex-pressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. | 08-15-2013 |
20130211050 | ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) - The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease. | 08-15-2013 |
20130211051 | FUSION PROTEIN CONTAINING VEGI, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF - Provided is an anti-angiogenic fusion protein, which comprises a vascular endothelial cell growth inhibitor (VEGI) or variant thereof, and other polypeptide such as IgG Fc. The fusion protein optionally comprises a linker. The fusion protein can induce the apoptosis of endothelial cells and inhibit the growtth of endothelial cells, so as to be used for treating tumor. Also provided are a pharmaceutical composition and use of the fusion protein. | 08-15-2013 |
20130217861 | METHODS FOR EXPRESSION AND PURIFICATION OF IMMUNOTOXINS - The present invention relates to a method of expressing an immunotoxin in | 08-22-2013 |
20130217862 | ANTIBODY MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR - The invention provides methods and compositions for modulating hepatocyte growth factor activator function. | 08-22-2013 |
20130217863 | Method to Improve Glycosylation Profile and to Induce Maximal Cytotoxicity for Antibody - The present invention relates to the production of recombinant glycoproteins or antibodies that have an improved glycosylation profile and effector functions such as ADCC and/or CDC. The present invention is in particular related to the production of glycoproteins or antibodies having a valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and/or presence of sialic acid to the glycans. | 08-22-2013 |
20130217864 | HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST - HYBRID FC FUSION PROTEIN - The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease. | 08-22-2013 |
20130231463 | Cell Display Of Antibody Libraries - The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics. | 09-05-2013 |
20130231464 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 09-05-2013 |
20130237690 | STABILIZING POLYPEPTIDES WHICH HAVE BEEN EXPOSED TO UREA - Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea. | 09-12-2013 |
20130237691 | USP2A PEPTIDES AND ANTIBODIES - The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment. | 09-12-2013 |
20130245229 | Neutralising Antibody Molecules Having Specificity for Human IL-17 - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 09-19-2013 |
20130245230 | Unnatural Reactive Amino Acid Genetic Code Additions - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 09-19-2013 |
20130245231 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYE - The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist. | 09-19-2013 |
20130245232 | HIGHLY EFFECTIVE ANTI-CADHERIN ANTIBODY FOR INDUCTION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY IN VIVO - It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 μg/mL is 30% or more. | 09-19-2013 |
20130245233 | Multispecific Molecules - The present invention is directed to multi-specific/multivalent molecules of novel formats. The molecules with the formats of the present invention have desired yield and thermostability. The present invention also includes methods of producing and using the molecules described herein. | 09-19-2013 |
20130253172 | Method for Making Heteromultimeric Molecules - The present invention provides methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising said molecules. The method includes introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered. | 09-26-2013 |
20130261287 | ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES - Methods for designing optimized antibodies, including optimized humanized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them. | 10-03-2013 |
20130261288 | METHOD FOR THE PRODUCTION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS - The present disclosure relates to an improved method for the manufacture of immunoglobulin single variable domains. More specifically, the present disclosure relates to a method of producing immunoglobulin single variable domains in which the proportion of carbamylated variants is strongly reduced or absent and to improved immunoglobulin single variable domains obtainable by methods of the present disclosure. | 10-03-2013 |
20130261289 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 10-03-2013 |
20130267685 | B7-H3 and B7-H4, Novel Immunoregulatory Molecules - The invention provides novel B7-H3 and B7-H4 polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 10-10-2013 |
20130267686 | BISPECIFIC ANTIBODIES COMPRISING A DISULFIDE STABILIZED - FV FRAGMENT - The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 10-10-2013 |
20130274446 | FRAGMENT OF HUMANIZED ANTI-EGFR ANTIBODY SUBSTITUTED-LYSINE VARIABLE FRAGMENT AND USE THEREOF - The purpose of the present invention is to provide fragments of humanized anti-EGFR antibody substituted-lysine light-chain or heavy-chain variable regions, and single-chain antibodies, etc, comprising the same, having sufficient binding activity (affinity) with target cells, and having the ability to undergo various site-specific and uniform chemical modifications. The present invention pertains to a humanized variable region on the light-chain or heavy-chain of antibody 528 against human epidermal cell growth factor receptor 1 (Her-1), said variable region comprising the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, wherein fragments of humanized anti-EGFR antibody lysine-substituted light-chain variable regions are formed by substituting a different amino acid for all of the lysine residues, or all of the lysine residues except for the lysine residue(s) of one specified moiety. | 10-17-2013 |
20130274447 | HUMANIZED ANTIBODIES AGAINST CXCR3 - Disclosed are humanized antibodies that bind specifically to the receptor CXCR3. The humanized antibodies may be antagonists and may be used to treat or diagnose conditions associated with CXCR3 function. | 10-17-2013 |
20130274448 | METHOD FOR PREVENTING MYOCARDIAL INFARCTION-RELATED COMPLICATIONS - The present invention is concerned with treatment, prevention, or prevention of progression of myocardial infarction or adverse cardiac remodeling related conditions such as heart failure, aneurysm formation and remote myocardial fibrosis by administering a binding member such as, for example, a neutralizing antibody, binding to fibronectin-EDA, in particular the EDA domain of fibronectin-EDA to a subject in need thereof. | 10-17-2013 |
20130296536 | NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF - The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth. | 11-07-2013 |
20130303733 | Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 11-14-2013 |
20130303734 | NOVEL HOMOGENEOUS HUMANIZED ANTIPROLIFERATION ANTIBODIES - The present disclosure relates to novel humanized antibodies able to inhibit tumor growth, as well as the amino and nucleic acid sequences coding for such antibodies. From one aspect, the disclosure relates to novel anti-JAM-A homogeneous humanized antibodies able to inhibit tumor growth. The disclosure also comprises the use of such antibodies as a drug for the preventive and/or therapeutic treatment of cancers, as well as compositions comprising such antibodies in combination with other anticancer compounds. The disclosure also relates to a method for the preparation of such novel humanized antibodies. | 11-14-2013 |
20130310541 | USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES - An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy. | 11-21-2013 |
20130310542 | Inotropic Effects of Antibodies on Cardiac Contraction - The present invention shows that site-specific antibodies to the (Na | 11-21-2013 |
20130317199 | Antibodies To Alpha-Synuclein - The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes. | 11-28-2013 |
20130317200 | Methods of Purifying Antibodies - The invention provides methods of purifying antibodies using various antibody-specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and/or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains. | 11-28-2013 |
20130317201 | ANTI-CDH3 ANTIBODY HAVING HIGH INTERNALIZATION CAPACITY - It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity. | 11-28-2013 |
20130324703 | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TRACT - In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract. | 12-05-2013 |
20130324704 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL | 12-05-2013 |
20130331553 | HUMAN TOLL HOMOLOGUES - The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein. | 12-12-2013 |
20130331554 | ENRICHMENT AND CONCENTRATION OF SELECT PRODUCT ISOFORMS BY OVERLOADED BIND AND ELUTE CHROMATOGRAPHY - Disclosed is a method for enhancing or increasing the concentration of biological product in a final mixture, wherein said biological product has one or more selected characteristics, wherein said method comprises: (a) allowing an initial mixture of biological products with and without said selected characteristics to contact a chromatography medium wherein the quantity of biological products in said initial mixture exceeds the binding capacity or the dynamic binding capacity of said chromatography medium; (b) allowing biological product not having said one or more selected characteristics to be separated by said chromatography medium; and (c) recovering a final mixture of biological products from said chromatography medium wherein said final mixture comprises an enhanced or increased concentration of biological product with one or more selected characteristics, compared to the concentration of biological product in said initial mixture. | 12-12-2013 |
20130338343 | COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASE - The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage. | 12-19-2013 |
20130345404 | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation - The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins. | 12-26-2013 |
20130345405 | BINDING MOLECULES - The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. | 12-26-2013 |
20130345406 | STABLE IGG4 ANTIBODIES - The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370). | 12-26-2013 |
20140005364 | SPECIFIC SORBENT FOR BINDING PROTEINS AND PEPTIDES, AND SEPARATION METHOD USING THE SAME | 01-02-2014 |
20140005365 | ANTIBODY TO A MUTANT G-CSF FOR DIAGNOSIS OF CANCER | 01-02-2014 |
20140005366 | GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES | 01-02-2014 |
20140005367 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | 01-02-2014 |
20140011981 | EXPRESSION AND SECRETION SYSTEM - The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules. | 01-09-2014 |
20140011982 | Antibodies Against Influenza Virus and Methods of Use Thereof - The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample. | 01-09-2014 |
20140018521 | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) - The invention relates to a method for identifying stabilizing amino acids in single chain antibody fragments. | 01-16-2014 |
20140018522 | Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification. | 01-16-2014 |
20140024809 | HLA-RESTRICTED, PEPTIDE-SPECIFIC ANTIGEN BINDING PROTEINS - Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function. | 01-23-2014 |
20140024810 | Modified Antibody Compositions, Methods of Making and Using Thereof - The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies. | 01-23-2014 |
20140031528 | METHOD FOR SELECTING PLASMA CELLS OR PLASMABLASTS, METHOD FOR PRODUCING TARGET ANTIGEN SPECIFIC ANTIBODIES, AND NOVEL MONOCLONAL ANTIBODIES - [Problem] To provide a method that efficiently produces antigen-specific monoclonal antibodies from a wide range of animal species, and to provide a new antigen-specific monoclonal antibody using this technique. [Solution] A nonhuman animal is immunized with a target antigen, lymph fluid or the like is collected from the immunized nonhuman animal, or lymph fluid or the like is collected from a human having antibodies to the target antigen, the collected lymph fluid or the like is combined with (1) a labeled target antigen and (2) a marker that can selectively binds to plasma cells and/or plasmablasts, and cells that have bound to (1) the labeled target antigen and (2) the marker are then selected. The plasma cells and or the plasmablasts that have specifically bound to the target antigen by the method are selected, an gene of an antibody for the target antigen is collected from the selected cells, the base sequence thereof is identified, an antibody or antibody fragment is prepared on the basis of the base sequence of the identified gene, and an antibody or antibody fragment specific to the target antigen is produced. | 01-30-2014 |
20140039162 | Displaying native human IgE neutralizing FceRla-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold - Vaccine displaying native antigenic loops of immunoglobulin E is critical for eliciting neutralizing anti-IgE antibodies. The embodiment of the invention enables the display of native antigenic IgE receptor-contacting loops as IgE B-cell vaccines via three steps of constraining methods. The loops of multiple antigenic B-cell epitopes can be molecularly grafted in, and conformationally constrained by the energy favorable flanking beta (b)-stands, i.e., the super b-strands identified in this invention. The constrained loops can be further stabilized in replacing a selective loop within the cystine knot peptide. These dual constrained antigenic loops are then integrated onto thermostable protein scaffolds, folded in the oxidative milieu that provides further conformational constraint and high yield. | 02-06-2014 |
20140039163 | CHOLESTEROL-DEPENDENT CYTOLYSIN VARIANT AND USE THEREOF IN DDS - The present invention provides a carrier capable of delivering a medical agent capsule encapsulating a medical agent to various target cells and tissues to cause the medical agent to be taken therein in an efficient and highly safe manner, and a drug delivery system using the carrier. The carrier has a cell or tissue specific antibody bound to an antibody binding domain of a cholesterol-dependent cytolysin variant of the present invention. The carrier can also have bound thereto, as a transport material, a functional cell or a cholesterol-containing microcapsule filled with a medicinal ingredient or a bioactive substance via domain 4 of the variant. | 02-06-2014 |
20140046030 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE - Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis. | 02-13-2014 |
20140046031 | Anti-IL-23 Antibodies, Compositions, Methods and Uses - An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 02-13-2014 |
20140046032 | METHOD OF PRODUCTION OF SIALYLATED ANTIBODIES - The present invention relates to a method for producing an IgG antibody, wherein at least 80% of the said antibody comprises a complex, bi-antennary oligosaccharide, which contains two sialic acid residues, attached to the Fc domain of the antibody. The said method comprises the steps of introducing a mutation in the Fc domain of the antibody, and expressing the mutant antibody in a cell which expresses a galactosyltransferase and a sialyltransferase activity. | 02-13-2014 |
20140046033 | ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE - The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The antibodies or compositions comprising the antibodies can be used to treat disease in which ADCC activity provides a benefit. In one embodiment, therefore, the antibodies or compositions comprising the antibodies can be used to treat cancer, lymphoproliferative disease or autoimmune disease. | 02-13-2014 |
20140046034 | ANTIBODY HAVING ACTIVITY OF INHIBITING HEPATITUS C VIRUS (HCV) INFECTION AND USE THEREOF - An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so as to be able to inhibit the binding of hepatitis C virus to the surface of a host cell and to inhibit HCV infection, a humanized antibody thereof, and an inhibitory agent for infection with hepatitis C virus. | 02-13-2014 |
20140051833 | Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format - The invention relates to antigen-binding proteins or antibodies having heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least one or two amino acid(s) that allows for isolation of the antigen-binding protein based on a differential affinity of an immunoglobulin heavy chain and a modified/mutated immunoglobulin heavy chain toward an affinity reagent. The invention also relates antigen-binding proteins, including bispecific antibodies, having IgG CH1 regions with different affinities with respect to affinity reagent(s) that allows rapid isolation by differential binding of the IgG regions to the affinity reagent(s). | 02-20-2014 |
20140051834 | Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function - Herein is reported an Fc-region fusion polypeptide or Fc-region conjugate comprising one to four incretin receptor ligand polypeptides and a variant human Fc-region with a mutation of the amino acid residue at position 329 and at least one further mutation of at least one amino acid selected from the group comprising amino acid residues at position 228, 233, 234, 235, 236, 237, 297, 318, 320, 322 and 331 to a different residue, wherein the residues in the Fc-region are numbered according to the EU index of Kabat and its use as a medicament. | 02-20-2014 |
20140051835 | Process and Methods for Efficient Manufacturing of Highly Pure Asymmetric Antibodies in Mammalian Cells - The present invention provides a process and methods for producing asymmetric antibodies in a mammalian expression system. The asymmetric antibodies are transiently or stably expressed and in cells that stably express the asymmetric antibody, following a rapid 2-step process of stable pool to clone, a highly pure asymmetric antibody expressing clone can be identified at a success frequency that permits for screening of tens of clones rather than thousands. The asymmetric antibodies are produced at a high titre and with a high level of purity with no contaminating homodimer antibodies following protein A purification with a step yield of near 100%. Typical downstream purification processes employ standard hydrophobic interaction chromatography (HIC) and/or cation exchange (CEX) resins and the antibody is stable within a wide dynamic range of buffer pH (4-8) and within the requirements for manufacturing antibodies for pre-clinical and clinical applications. | 02-20-2014 |
20140051836 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use - Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis. | 02-20-2014 |
20140066599 | Hetero-Dimeric Immunoglobulins - The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same. | 03-06-2014 |
20140066600 | NOVEL LOWERED AFFINITY ANTIBODIES AND USES THEREFOR - The present invention provides novel, rationally designed lowered affinity antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall 3 dimensional antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects. | 03-06-2014 |
20140066601 | ALPHABODY LIBRARIES AND METHODS FOR PRODUCING THE SAME - The invention provides single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein at least 70% but not all of said variegated amino acid residue positions are located either in the loop, helix surface or linker region of the Alphabody. The invention further provides methods for use of the Alphabody libraries and Alphabodies obtainable by the methods of the invention. | 03-06-2014 |
20140066602 | PEPTIDES FOR TREATMENT AND DIAGNOSIS OF BONE DISEASES - The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide. | 03-06-2014 |
20140066603 | ANTI-RON ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON. | 03-06-2014 |
20140073767 | PROTEIN COMPLEXES AND METHODS OF MANUFACTURING BISPECIFIC ANTIBODIES USING THE PROTEIN COMPLEXES - A protein complex comprising (i) a first fusion protein comprising (a) a first polypeptide that comprises a first antigen-binding site and (b) a first binding protein linked to a terminus of the first polypeptide; and (ii) a second fusion protein comprising (a) a second polypeptide that comprises a second antigen-binding site and (b) a second binding protein linked to a terminus of the second polypeptide, wherein the protein complex comprises an amino acid sequence that enables cleavage between the first polypeptide and the first binding protein, and/or between the second polypeptide and the second binding protein, as well as a method for preparing a bi-specific antibody and related methods and compositions. | 03-13-2014 |
20140073768 | OPTIMIZED Fc VARIANTS - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 03-13-2014 |
20140081002 | PROTEIN COMPLEX INCLUDING BI-SPECIFIC ANTIBODY - Provided is a protein complex including a bi-specific antibody, and a method of preparing the protein complex, which can provide a system that simultaneously targets two antigens. | 03-20-2014 |
20140088295 | ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF - The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders. | 03-27-2014 |
20140094593 | Purification method for proteins, in particular antibodies, utilizing a wash solution comprising arginine at high pH for the affinity chromatography step - The invention provides a washing method for affinity chromatography in which a wash solution comprising arginine, or an arginine derivative, at pH greater than 8.0, is effective in removing impurities without the presence of a nonbuffering salt, while simultaneously increasing product concentration in the eluate and maintaining a high percent yield of recovered product. | 04-03-2014 |
20140100359 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 04-10-2014 |
20140107322 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 04-17-2014 |
20140114054 | ANTIBODY CAPABLE OF SPECIFICALLY RECOGNIZING TRANSFERRIN RECEPTOR - An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3). | 04-24-2014 |
20140121358 | HUMANIZED ANTIBODY AND PROCESS FOR PREPARING SAME - A humanized antibody is produced by process comprising the steps of: (a) selecting a specificity determining residue (SDR) of the complementarity determining region (CDR) of murine monoclonal antibody heavy chain and light chain variable regions; and (b) grafting said SDR to at least one of the corresponding amino acid sequences in human antibody variable regions. | 05-01-2014 |
20140128575 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES - The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures. | 05-08-2014 |
20140128576 | Anti-IL-23 Antibodies, Compositions, Methods and Uses - An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 05-08-2014 |
20140128577 | PURIFICATION OF CHIMERIC PROTEIN - Provided is a method for purification of TNFR:Fc fusion protein comprising hydrophobic interaction chromatography, wherein the buffer solution used in the said chromatography does not contain any additives. | 05-08-2014 |
20140135480 | Compositions and Methods for the Therapy and Diagnosis of Influenza - The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. | 05-15-2014 |
20140135481 | HUMANIZED MONOCLONAL ANTIBODIES THAT PROTECT AGAINST SHIGA TOXIN INDUCED DISEASE - The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention. | 05-15-2014 |
20140135482 | Bispecific Anti ErbB3 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-3 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 05-15-2014 |
20140148581 | NOVEL HA BINDING AGENTS - This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use. | 05-29-2014 |
20140148582 | NUCLEIC ACIDS ENCODING BIOLOGICALLY ACTIVE POLYPEPTIDES DERIVED FROM A NOVEL EARLY STAGE PREGNANCY FACTOR DESIGNATED MATERNIN (MA) - The invention relates to nucleotides encoding therapeutic polypeptides and fragments thereof isolated from beta-human chorionic gonadotropin (β-hCG) found in early pregnancy urine, now synthetically produced and designated Maternin. The therapeutic polypeptides and their functional equivalents are useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, pro-hematopoietic (e.g., anemias, radiation-mediated bone marrow damage, and trauma-mediated blood loss), and anti-angiogenic effects. The invention also provides pharmaceutical compositions comprising the therapeutic polypeptides, as well as methods for using the therapeutic polypeptides, functional equivalents and/or pharmaceutical compositions in the treatment and/or prevention of such medical conditions. | 05-29-2014 |
20140148583 | ANTIBODY INDUCING ANTIGEN-SPECIFIC T CELL TOLERANCE AND USE THEREOF - The present invention relates to an antibody binding to the domain 2 of human intercellular adhesion molecules-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and induce antigen-specific T cell tolerance, thereby be effective in the prevention and/or treatment of T cell-mediated immune disorders such as transplantation rejection, graft-versus-host disease, and autoimmune disease. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease. | 05-29-2014 |
20140155579 | DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING - Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1α and IL-β) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental. | 06-05-2014 |
20140155580 | TRANSGENIC AVES PRODUCING HUMAN POLYCLONAL ANTIBODIES - Human antibodies are produced in transgenic chickens having functional genetic components of the human immune system stably integrated in the genome. Techniques are described to integrate unrearranged human heavy and light chain immunoglobulin loci into the genome of the transgenic chicken. | 06-05-2014 |
20140155581 | Methods For Making Multimeric Polypeptides - Detailed herein are contiguous, multimeric, multispecific polypeptides, nucleic acids encoding such polypeptides, and methods for making such polypeptides and nucleic acids. | 06-05-2014 |
20140171621 | Galectin-Immunoglobulin Chimeric Molecules - Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers. | 06-19-2014 |
20140171622 | FUSION PROTEINS FORMING TRIMERS - The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein. | 06-19-2014 |
20140171623 | Modulation Of Antibody Effector Function By Hinge Domain Engineering - The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes. | 06-19-2014 |
20140187751 | PURIFICATION OF FUSION PROTEINS - The invention relates generally to methods for purifying a Fc-fusion protein produced in a eukaryotic expression system. More specifically, the invention provides a robust and scalable downstream purification process suitable for use in manufacturing TNFR:Fc for human administration which comprises an optimized Protein A affinity chromatography step and two ion exchange chromatography steps both of which are operated in the bind-and-elute mode. | 07-03-2014 |
20140187752 | ANTIGENIC COMPOSITIONS AND USE OF SAME IN THE TARGETED DELIVERY OF NUCLEIC ACIDS - Methods and compositions are provided for delivery of therapeutic nucleic acids to a target cell. A chimeric antigen is provided to encapsulate, bind, or otherwise carry a nucleic acid molecule to a target cell where the chimeric antigen and nucleic acid are internalized, for example by receptor-mediated endocytosis. The chimeric antigen has a nucleic acid interaction domain, a target binding domain, and an immune response domain that may include a target antigen. Targeting is generally provided by the specificity of the target binding domain for a particular target cell receptor, but may also be provided by inclusion of a targeting antigen within the immune response domain. The combined delivery of chimeric antigen and nucleic acid, which may be a siRNA, may be synergistic in certain applications, for example in breaking host tolerance to a virus or in providing immunostimulation. | 07-03-2014 |
20140187753 | Hetero-Dimeric Immunoglobulins - The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same. | 07-03-2014 |
20140187754 | ANTI-FGFR3 ANTIBODIES AND METHODS USING SAME - The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies. | 07-03-2014 |
20140194596 | Dual Specificity Antibody Fusions - The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest. | 07-10-2014 |
20140194597 | MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES - The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component. | 07-10-2014 |
20140194598 | B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION - The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject. | 07-10-2014 |
20140200331 | Engineered Immunoglobulin Heavy Chain-Light Chain Pairs And Uses Thereof - The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the C | 07-17-2014 |
20140206846 | Dual Targeting - The present invention relates to antibody-based dual targeting molecules, and to methods for generating such dual targeting molecules, including a library-based approach. | 07-24-2014 |
20140206847 | MUTANT PROTEIN CAPABLE OF BINDING SPECIFICALLY AND QUICKLY TO TROPONIN I DERIVED FROM HUMAN MYOCARDIUM - Provided is a mutant protein capable of binding specifically and quickly to troponin I derived from human myocardium. The mutant protein comprises a first mutant scFv antibody fragment | 07-24-2014 |
20140206848 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS - The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention. | 07-24-2014 |
20140213768 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 07-31-2014 |
20140213769 | FUSION PROTEIN FOR SUPPRESSING CANCER CELL GROWTH AND SUPPRESSING VASCULOGENESIS, AND ANTICANCER COMPOSITION COMPRISING SAME - The present invention relates to a fusion protein resulting from the fusion of a cancer-specific antibody and an angiogenesis inhibitor, and relates to an anti-cancer composition including the same. More specifically, in the present invention, it is preferable that the cancer-specific antibody is trastuzumab or a fragment thereof, and the angiogenesis inhibitor is a VEGF-Trap. When the fusion protein according to the present invention is used, there are advantages in that angiogenesis and cancer cell growth can be effectively inhibited as compared to trastuzumab or VEGF-Trap, and side effects can also be reduced. | 07-31-2014 |
20140213770 | HIGH-THROUGHPUT ANTIBODY HUMANIZATION - The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation. | 07-31-2014 |
20140213771 | MULTI-SPECIFIC BINDING PROTEINS - Engineered multi-specific binding proteins that bind to one or more target proteins (e.g., antigens) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 07-31-2014 |
20140213772 | CROSS-OVER DUAL VARIABLE DOMAIN IMMUNOGLOBULIN CONSTRUCTS - Engineered cross-over DVD-Ig binding proteins that bind to two or more target proteins (e.g., antigens) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 07-31-2014 |
20140213773 | ADAM6 MICE - Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided. | 07-31-2014 |
20140221620 | ANTI-HUMAN P-CADHERIN (CDH3) RECOMBINANT ANTIBODY - It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in SEQ ID NO: 38 that is the extracellular region of human CDH3, and has cytotoxicity against CDH3-expressing cells. | 08-07-2014 |
20140221621 | SINGLE-CHAIN MULTIVALENT BINDING PROTEIN COMPOSITIONS AND METHODS - Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display). | 08-07-2014 |
20140221622 | MONOVALENT BINDING PROTEINS - Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. | 08-07-2014 |
20140221623 | INTERLEUKIN-6 RECEPTOR BINDING POLYPEPTIDES - The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor. | 08-07-2014 |
20140221624 | HUMANIZATION OF RABBIT ANTIBODIES USING A UNIVERSAL ANTIBODY FRAMEWORK - The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications. | 08-07-2014 |
20140235827 | MOUSE ANTI-AGGRUS MONOCLONAL ANTIBODIES - The present invention provides a monoclonal antibody or a functional fragment thereof, capable of recognizing Aggrus epitope comprising an amino-acid sequence represented by a sequence ID 1, 3, or 4, and the monoclonal antibody or the functional fragment thereof produced from a hybridoma with deposit ID of FERM BP-11446, FERM BP-11447, FERM BP-11448 or FERM BP-11449. The present invention provides the hybridoma, and further an Aggrus-CLEC-2 binding inhibitor and a pharmaceutical composition for inhibition of platelet aggregation, prevention of cancer metastasis, or treatment of tumor or cancer, comprising the monoclonal antibody or the functional fragment thereof. | 08-21-2014 |
20140235828 | GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS - The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals. | 08-21-2014 |
20140235829 | Compositions And Methods For Regulation Of Tumor Necrosis Factor-Alpha - The present invention relates to compositions and methods relating to an interleukin 18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression. | 08-21-2014 |
20140235830 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 08-21-2014 |
20140243502 | Anticoagulation agent and uses thereof - The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders. | 08-28-2014 |
20140243503 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 08-28-2014 |
20140243504 | ANTIBODIES COMPRISING CHIMERIC CONSTANT DOMAINS - Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided. | 08-28-2014 |
20140243505 | BISPECIFIC ANTIBODY - Provided are bispecific antibodies comprised of a single-chain unit having specificity to an immune cell and a monovalent unit having specificity to a tumor cell or a microorganism. The single-chain unit includes a single-chain variable fragment (scFv) fused to an Fc fragment and the monovalent unit includes a light chain and heavy chain pair. Also provided are methods of preparing bispecific antibodies and pharmaceutical and diagnostic uses of these antibodies. | 08-28-2014 |
20140243506 | ANTAGONISTS OF IL17C FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder. | 08-28-2014 |
20140249296 | USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR PROTEIN LIGATION - Methods and reagents for the installation of click chemistry handles on target proteins are provided, as well as modified proteins comprising click chemistry handles. Further, chimeric proteins, for example, bi-specific antibodies, that comprise two proteins conjugated via click chemistry, as well as methods for their generation and use are disclosed herein. | 09-04-2014 |
20140249297 | ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS - The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo. | 09-04-2014 |
20140256915 | Velocity Factor - The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method. | 09-11-2014 |
20140256916 | IMMUNO IMAGING AGENT FOR USE WITH ANTIBODY-DRUG CONJUGATE THERAPY - The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6. | 09-11-2014 |
20140275485 | LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE - The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject. | 09-18-2014 |
20140275486 | HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME - Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MOO-modified antibodies in the production of Adalimumab TNF-alpha antibodies. | 09-18-2014 |
20140275487 | BINDING DOMAINS DIRECTED AGAINST GPCR:G PROTEIN COMPLEXES AND USES DERIVED THEREOF - The present invention relates to the field of G protein coupled receptor (GPCR) structural biology and signaling. In particular, the present invention relates to binding domains directed against and/or specifically binding to GPCR:G protein complexes. Also provided are nucleic acid sequences encoding such binding domains and cells expressing or capable of expressing such binding domains. The binding domains of the present invention can be used as universal tools for the structural and functional characterization of G-protein coupled receptors in complex with downstream heterotrimeric G proteins and bound to various natural or synthetic ligands, for investigating the dynamic features of G protein activation, as well as for screening and drug discovery efforts that make use of GPCR:G protein complexes. | 09-18-2014 |
20140275488 | HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF - The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment. | 09-18-2014 |
20140275489 | APELIN FUSION PROTEINS AND USES THEREOF - The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or a variant of an Fc domain. Apelin Fc-fusion polypeptides are capable of binding to the apelin receptor (APLNR). Apelin Fc-fusion polypeptides are capable of activating the APLNR and have improved pharmacokinetic properties compared to apelin peptides that are not fused to an Fc or an Fc fragment. Apelin Fc-fusion polypeptides are useful in diseases and conditions related to cardiovascular function, diabetes, cancer, obesity and other apelin-related conditions. | 09-18-2014 |
20140288273 | MACROMOLECULAR COMPOSITIONS THAT CROSS THE BLOOD-BRAIN BARRIER AND METHODS OF USE THEREOF - The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease. | 09-25-2014 |
20140288274 | HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF - The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment. | 09-25-2014 |
20140288275 | NOVEL HETERODIMERIC PROTEINS - The invention provides novel heterodimeric proteins including heterodimeric antibodies. | 09-25-2014 |
20140288276 | HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR - The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods. | 09-25-2014 |
20140296488 | ANTI-NOTCH NRR ANTIBODIES AND METHODS USING SAME - The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies. | 10-02-2014 |
20140296489 | Protein Production Method - Production of etanercept using perfusion methods achieves attractive yields of properly folded protein. Desired temperature, feed media, titers and percent correctly folded protein are disclosed. | 10-02-2014 |
20140296490 | HIGHLY GALACTOSYLATED ANTIBODIES - In one aspect, the disclosure relates to antibodies that are highly galactosylated, methods of production of these antibodies and methods of use of these antibodies. | 10-02-2014 |
20140296491 | GENERATING METAL ION BINDING PROTEINS - The present invention provides for a method for generating a metal ion binding protein, the method comprising a) integrating the amino acid sequence DDD into CDR1 of a light chain variable region of an antibody or fragment thereof; and b) combining the sequence of step a) with a heavy chain variable region of an antibody or fragment thereof; and c) isolating the protein. Also provided is the use of metal ion binding proteins generated by the method of the present invention for isolation and purification of proteins and for the reversible labeling of a target molecule. Also provided is a metal ion binding anti-CD8 protein. | 10-02-2014 |
20140296492 | HLA-RESTRICTED, PEPTIDE-SPECIFIC ANTIGEN BINDING PROTEINS - Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function. | 10-02-2014 |
20140303354 | Anti-CD47 Antibodies and Methods of Use Thereof - The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19. | 10-09-2014 |
20140303355 | Humanized Anti-Factor D Antibodies And Uses Thereof - The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 10-09-2014 |
20140303356 | PRODUCTION OF HETERODIMERIC PROTEINS - The present invention relates to an in vitro method for production of heterodimeric proteins. | 10-09-2014 |
20140309403 | NOVEL PROTEIN PURIFICATION METHODS - The invention provides methods of reducing fouling of ultrafiltration membranes in processes wherein virus particles are removed from aqueous solutions comprising virus particles and at least one protein by adding a surfactant or non-surfactant, non-ionic agent to the aqueous solution prior to filtration. The invention also provides methods to dissociate protein aggregates or to reduce the formation of protein aggregates by adding a surfactant or non-surfactant, non-ionic agent to the protein solution. | 10-16-2014 |
20140316113 | METHOD FOR THE HUMANIZATION OF ANTIBODIES AND HUMANIZED ANTIBODIES THEREBY OBTAINED - Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies. | 10-23-2014 |
20140316114 | METHOD FOR PREPARING ACTIVE FORM OF TNFR-FC FUSION PROTEIN - The present invention relates to a method for separating and preparing a TNFR-Fc fusion protein using hydrophobic interaction chromatography (HIC). More particularly, the present invention relates to a method for separating and preparing a highly pure active protein from clipped proteins due to displacement effect by adjusting the conductivity of a protein sample using a high concentration of salt solution and by adjusting a loading amount thereof, and a TNFR-Fc fusion protein prepared by the method. | 10-23-2014 |
20140316115 | METHOD OF ANTIBODY PURIFICATION - The present invention relates to a method for preparing a population of antibodies to have high purity and high quality by removing antibody isoforms and impurities through the use of a cation exchange column, a hydrophobic interaction column, and an anion exchange column successively, without using a protein A column; and to a population of antibodies prepared by the above method. | 10-23-2014 |
20140323696 | Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods - The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide. | 10-30-2014 |
20140323697 | MEDIA FOR AFFINITY CHROMATOGRAPHY - The invention relates generally to solid supports for chromatography. In specific embodiments the invention provides for solid supports suitable for affinity chromatography along with methods, systems and kits which use the same. | 10-30-2014 |
20140323698 | PROTEIN PURIFICATION USING BIS-TRIS BUFFER - The invention provides a two-step chromatography process for small and large-scale purification of proteins, specifically monoclonal antibodies, using only four buffer solutions made from a mother solution. | 10-30-2014 |
20140336360 | Tyrosine, Serine and Threonine Phosphorylation Sites - The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 11-13-2014 |
20140336361 | ASSEMBLY OF BISPECIFIC ANTIBODIES - Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding to more than one target molecule or different epitopes on a single target molecule. The methods modulate parameters to improve assembly of the heteromultimeric proteins at higher yield and efficiency than otherwise possible. Also described are compositions comprising a hinge-containing polypeptide, such as a half-antibody. | 11-13-2014 |
20140336362 | Avian Derived Antibodies - The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produces in a transgenic avian. The antibody molecules have a heavy chain and a light chain and exhibit an increased level of antibody-dependent cell-mediated cytotoxicity (ADCC) as compared to that of anti-CD20 antibody molecules produced by CHO cells. | 11-13-2014 |
20140336363 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 11-13-2014 |
20140343256 | TLR2 ANTAGONISTIC ANTIBODY AND USE THEREOF - The present invention is directed to a cross-reactive antibody, which specifically inhibits or blocks the mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of said antibody. It is further providing a pharmaceutical composition comprising said antibody, nucleic acid or vector and is directed to the use of said composition in the prevention and/or treatment of inflammatory processes or any other process induced by bacterial infection, trauma, or chronic inflammation, or for the prevention and/or treatment of bacteriaemia or sepsis. | 11-20-2014 |
20140343257 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 11-20-2014 |
20140350225 | ANTI-BFGF HUMANIZED DOUBLE-STRANDED ANTIBODY WITH STABLE DISULFIDE BOND, PREPARATION METHOD AND APPLICATION THEREOF - Disclosed are an anti-bFGF humanized double-stranded antibody with stable disulfide bond, the preparation method and the applications thereof. The amino acid sequence of the anti-bFGF humanized ds-Diabody is shown in SEQ ID NO. 1. The nucleotide sequence of gene encoding the anti-bFGF humanized ds-Diabody is shown in SEQ ID NO. 2. By site-directed mutation, two cysteine residues are introduced into each single-stranded antibody, thus introducing the disulfide bond and form ds-Diabody. It is shown by experiments that the obtained ds-Diabody has the following advantages: enhanced stability; better affinity when binding to the specific antigen bFGF; moderate relative molecular weight, good tumor targeting, more powerful in tumor tissue penetration, and higher blood clearance rate, showing a broad application prospects in the clinic diagnosis and tumor therapy. | 11-27-2014 |
20140350226 | RSPONDINS AS MODULATORS OF ANGIOGENESIS AND VASCULOGENESIS - The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis. | 11-27-2014 |
20140357843 | IMMUNOGLOBULIN FC VARIANTS - The present invention relates to immunoglobulin Fc variants having an increased binding affinity for FcRn, which is characterized by including one or more amino acid modifications selected from the group consisting of 307S, 308F, 380S, 380A, 428L, 429K, 430S, 433K and 434S (this numbering is according to the EU index) in the constant region of a native immunoglobulin Fc fragment. Owing to the high binding affinity for FcRn, the immunoglobulin Fc variants according to the present invention show more prolonged in vivo half-life, and thus can be used for the preparation of a long-acting formulation of protein drugs. | 12-04-2014 |
20140364590 | DLL3 MODULATORS AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 12-11-2014 |
20140371428 | ANTI-GLUCOSAMINIDASE PASSIVE IMMUNIZATION FOR STAPHYLOCOCCUS AUREUS INFECTIONS - The present invention is directed to a monoclonal antibody that binds specifically to a | 12-18-2014 |
20140378663 | FC VARIANTS WITH REDUCED EFFECTOR FUNCTIONS - A method for producing a variant of a parent polypeptide including a Fc region, which variant exhibits reduced binding to the protein C1q and to at least one receptor Fcgγ R as compared to the parent polypeptide. | 12-25-2014 |
20140378664 | PROTEIN COMPLEX, BISPECIFIC ANTIBODY INCLUDING THE PROTEIN COMPLEX, AND METHOD OF PREPARATION THEREOF - A protein complex comprising a first polypeptide comprising a first antigen-binding region; a second polypeptide comprising a second antigen-binding region; and | 12-25-2014 |
20140378665 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES - GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. | 12-25-2014 |
20140378666 | DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING - Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1α and IL-1β) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental. | 12-25-2014 |
20150018526 | Cytotoxins comprising modified bouganin toxin for the treatment of cancer - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. | 01-15-2015 |
20150018527 | METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY - This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided. | 01-15-2015 |
20150018528 | Antibodies That Bind Peptidoglycan Recognition Protein 1 - Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments. | 01-15-2015 |
20150018529 | Sequence Symmetric Modified IgG4 Bispecific Antibodies - The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations. | 01-15-2015 |
20150018530 | Novel Prodrug Containing Molecule Compositions and Their Uses - Novel prodrug compositions and uses thereof are provided. | 01-15-2015 |
20150031860 | HUMAN ANTIBODIES AND PROTEINS - The present invention provides composite proteins, including antibodies, which show reduced immunogenicity. In particular, composite antibodies for use in humans are provided, in particular antibodies which have been modified to remove one or more T-cell epitopes. Methods for generating such proteins are also provided. | 01-29-2015 |
20150031861 | Chemical Modification of Antibodies - The present invention relates to antibodies and antibody fragments, one or more of whose native inter-chain disulfide bridges have been replaced with a specific bridging moiety. The bridging moiety can be selectively targeted to inter-chain disulfide bonds within the antibody or antibody fragment, enabling the construction of more homogenously modified products such as antibody-drug conjugates. | 01-29-2015 |
20150031862 | OPTIMIZED Fc VARIANTS - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 01-29-2015 |
20150038682 | ANTIBODIES OR FUSION PROTEINS MULTIMERIZED VIA HOMOMULTIMERIZING PEPTIDE - The invention provides antibodies or fusion proteins with modified heavy chain IgG constant regions that promote assembly of multimeric complexes. Within an antibody or fusion protein unit there are two heavy chains each including at least CH2 and CH3 regions. The two heavy chains bear complementary modifications (e.g., knob and hole) to promote coupling of the heavy chains within a unit. One and only one of the heavy chains in a unit is fused at its C-terminus to a homomultimerizing peptide. The presence of the homomultimerizing peptide promotes association between units. For example, if the homomultimerizing peptide is a homotrimerizing peptide it promotes association of three units to form a trimeric complex. | 02-05-2015 |
20150045540 | MULTISPECIFIC STACKED VARIABLE DOMAIN BINDING PROTEINS - The present invention concerns multi-specific stacked variable domain binding proteins. | 02-12-2015 |
20150057436 | HUMANIZED ANTIBODIES - The invention relates to novel humanized antibodies derived from the conventional antibody repertoire of species in the family Camelidae. | 02-26-2015 |
20150065690 | MODIFIED ANTIBODY REGIONS AND USES THEREOF - The present invention relates to modified Fc regions of antibodies, and uses thereof, such as in antibodies that contain an Fc region of the present invention. | 03-05-2015 |
20150065691 | Anti-Cancer Antibodies With Reduced Complement Fixation - The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin. | 03-05-2015 |
20150073129 | Combination therapy of antibodies against human CSF-1R and antibodies agains human PD-L1 - The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-L1. | 03-12-2015 |
20150073130 | HYBRID CONSTANT REGIONS - The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and Cμ3 and Cμ4 regions of a Cμ constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a Cμ constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89. | 03-12-2015 |
20150080555 | METHOD FOR DECREASING IMMUNOGENICITY - A method for decreasing the immunogenicity of antibody variable domains is disclosed. | 03-19-2015 |
20150080556 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 03-19-2015 |
20150080557 | HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME - Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies. | 03-19-2015 |
20150087810 | Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof - The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications. | 03-26-2015 |
20150087811 | GLYCOPROTEIN SYNTHESIS AND REMODELING BY ENZYMATIC TRANSGLYCOSYLATION - A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery. | 03-26-2015 |
20150099861 | ANTI ALPHABETATCR ANTIBODY - The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties. | 04-09-2015 |
20150099862 | NOVEL HUMAN CONTROL ANTIBODIES AND USES THEREFOR - The present invention provides novel, rationally designed human control antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have well characterized variable domains that have been designed to minimize or eliminate antigen binding without altering gross antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects. | 04-09-2015 |
20150099863 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 04-09-2015 |
20150099864 | PREPARATION OF ORGANOPHOSPHATE PEPTIDE ADDUCTS - Disclosed are methods for the synthesis of organophosphorus-adducted peptides. Such peptides may be useful as biomarkers of organophosphate exposure, or for the synthesis of antibodies. Also disclosed are peptide adducts including peptide adducts of tabun, and aged adducts. | 04-09-2015 |
20150112045 | PRODUCTION OF SECRETED THERAPEUTIC ANTIBODIES IN MICROALGAE - Disclosed is a transformed microalga including a nucleic acid sequence operatively linked to a promoter, wherein the nucleic acid sequence encodes an amino acid sequence including (i) an heterologous signal peptide; and (ii) a therapeutic antibody, a functional fragment or a derivative thereof, the transformed microalga expressing the therapeutic antibody, functional fragment or derivative thereof secreted in the extracellular media and the microalga being selected among green algae except Volvocales, and among red algae, chromalveolates, and euglenids. Preferably, therapeutic antibody, functional fragment or derivative thereof has an increased antibody-dependant cell-mediated cytotoxicity (ADCC) and a low fucose content. The present invention also relates to a method for producing therapeutic antibody, a functional fragment or a derivative thereof, a functional fragment or a derivative thereof in the extracellular medium, to a therapeutic antibody, a functional fragment or a derivative thereof produced and secreted in the extracellular medium of microalgae. | 04-23-2015 |
20150112046 | ANTIBODY COMPOSITION-PRODUCING CELL - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependant cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 04-23-2015 |
20150119555 | BISPECIFIC ANTIBODY MOLECULE - The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells. | 04-30-2015 |
20150119556 | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same - A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence. Methods of making non-human animals that express antibodies comprising histidine residues encoded by histidine codons introduced into immunoglobulin light chain nucleotide sequences are provided. | 04-30-2015 |
20150133637 | P2X7 RECEPTOR ANTAGONISTS AND AGONISTS - The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP. | 05-14-2015 |
20150133638 | SINGLE-CHAIN ANTIBODIES AND OTHER HETEROMULTIMERS - The invention provides engineered heteromultimeric protein complexes constructed using one, two, or three tethers and methods for making, using, and purifying such complexes, such as antibodies with different binding properties. | 05-14-2015 |
20150133639 | Use of Metal Ions for Modulation of Protein Glycosylation Profiles of Recombinant Proteins - Protein glycosylation greatly influences the structure, function, and pharmacokinetics of recombinant proteins. Here, growth media supplemented with metal ions is shown to modulate the protein glycosylation profile of recombinant proteins expressed in a variety of eukaryotic cell lines. In particular, millimolar amounts of ferric salts (e.g. ferric nitrate, ferric citrate, etc.) significantly increased the percentage of galactosylated N-glycan species. The effect on protein glycosylation was concentration-dependent manner up to 1.0 mM across multiple cell lines without adverse effects on cell viability. The use of iron supplements in cell culture media provides an efficient and effective approach towards the specific re-targeting of N-glycan glycoform profiles of recombinantly expressed proteins. | 05-14-2015 |
20150133640 | Production of T cell retargeting hetero-dimeric immunoglobulins - The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique. | 05-14-2015 |
20150133641 | TRANSGENIC NON-HUMAN VERTEBRATE FOR THE IN VIVO PRODUCTION OF DUAL SPECIFICITY IMMUNOGLOBULINS OR HYPERMUTATED HEAVY CHAIN ONLY IMMUNOGLOBULINS - The invention relates, in one aspect, generally to novel concept of guided selection of antibody variable domains, combination and expression entirely in vivo. An application is to produce multivalent polypeptides. The present invention relates to multivalent (eg, multispecific) antibodies, antibody chains and polypeptides, as well as heavy chain-only antibodies (H2 antibodies) that are devoid of light chains. The invention further relates to the selection, maturation and production of these in vivo in non-human vertebrates and non-human vertebrate cells. To this end the invention also relates to such non-human vertebrates and cells. The invention also relates to the provision of means to produce and select heavy chain-only antibodies and heavy chains comprising variable domains that have undergone affinity maturation. | 05-14-2015 |
20150141620 | METHODS RELATED TO RITUXIMAB - The present invention relates to the characterization and production of rituximab. | 05-21-2015 |
20150141621 | STABILIZED HUMAN IGG4 ANTIBODIES - A highly stable mutant of human IgG4 antibody is provided. Such antibody is an antibody in which the CH3 domain of human IgG4 is substituted with the CH3 domain of human IgG1 and which exhibits inhibited aggregate formation, an antibody in which the CH3 and CH2 domains of human IgG4 are substituted with the CH3 and CH2 domains of human IgG1, respectively, or an antibody in which arginine at position 409 indicated in the EU index proposed by Kabat et al. of human IgG4 is substituted with lysine and which exhibits inhibited aggregate formation. | 05-21-2015 |
20150141622 | FLT4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY - The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor. | 05-21-2015 |
20150289489 | NON-HUMAN ANIMALS THAT MAKE SINGLE DOMAIN BINDING PROTEINS - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises (a) a deletion in an immunoglobulin constant region C | 10-15-2015 |
20150291697 | ANTIBODY CAPABLE OF SPECIFICALLY RECOGNIZING TRANSFERRIN RECEPTOR - The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively. | 10-15-2015 |
20150291700 | Sodium Pump Antibody Agonists And Methods Of Treating Heart Disease Using The Same - Antibodies that are agonists of sodium pump (Na | 10-15-2015 |
20150291704 | METHOD FOR THE PRODUCTION AND SELECTION OF MOLECULES COMPRISING AT LEAST TWO DIFFERENT ENTITIES AND USES THEREOF - Herein is reported a method for producing a polypeptide comprising at least two polypeptide domains comprising the step of cultivating a cell comprising (a) a nucleic acid encoding a soluble | 10-15-2015 |
20150299296 | FCgammaRIIB-SPECIFIC FC REGION VARIANT - An objective of the present invention is to provide an Fc region variant with enhanced FcγRIIb-binding activity, and/or enhanced binding selectivity to FcγRIIb compared to FcγRIIa (type R), as compared to those of a polypeptide containing an Fc region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing FcγRIIb-binding activity and also enhancing binding selectivity to FcγRIIb compared to FcγRIIa (type R). | 10-22-2015 |
20150299304 | Modulation of the VPS10P-Domain Receptors for the Treatment of Cardiovascular Disease - The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of abnormal plasma lipid concentrations and associated diseases and/or disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo. | 10-22-2015 |
20150299331 | MODIFIED GLYCOPROTEINS - Modified glycoproteins, and methods of making and using such modified glycoproteins, are described. | 10-22-2015 |
20150299332 | MEDICAMENT COMPRISING ACTIVITY MODULATOR FOR CD300a-EXPRESSING CELL ASSOCIATED WITH ALLERGIC DISEASE, CD300a GENE-DEFICIENT MOUSE, AND USE OF ACTIVITY MODULATOR FOR CD300a-EXPRESSING CELL - The present invention provides medicaments for allergic diseases (atopic dermatitis, asthma, and the like), and a tool useful for pathology analysis of allergic diseases. A medicament containing as an effective component an activity modulator for suppressing inhibitory signal transduction of a CD300a-expressing myeloid cell, which activity modulator contains a substance that inhibits binding of CD300a to phosphatidyl serine, can be used for treatment or prophylaxis of an allergic disease. A CD300a gene-deficient mouse can be used as a model mouse in which the allergic disease is hardly induced after administration of a substance that induces the allergic disease, which may be used for carrying out pathology analysis of an allergic disease, or for screening of a possible candidate substance for an effective component of a therapeutic agent or prophylactic agent for the disease. | 10-22-2015 |
20150307551 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF - The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer. | 10-29-2015 |
20150307600 | ANTI-PHF-TAU ANTIBODIES AND THEIR USES - Anti-PHF-tau antibodies and methods of making and using them are disclosed. | 10-29-2015 |
20150307604 | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TRACT - In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract. | 10-29-2015 |
20150307615 | HUMANIZED ANTI-INTERLEUKIN 3 RECEPTOR ALPHA CHAIN ANTIBODIES - The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof. | 10-29-2015 |
20150307621 | ANTI-CD98 ANTIBODY PROCESSES - A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided. | 10-29-2015 |
20150307628 | CH3 DOMAIN VARIANT PAIR INDUCING FORMATION OF HETERODIMER OF HEAVY CHAIN CONSTANT REGION OF ANTIBODY AT HIGH EFFICIENCY, METHOD FOR PREPARING SAME, AND USE THEREOF - Disclosed are a CH3 domain variant pair of an antibody, a method for preparing same, and a use thereof. A mutation is induced in the CH3 domain so as to improve a yield of forming a heterodimer heavy chain constant region of an antibody. The CH3 domain heterodimer forms a heterodimer heavy chain constant region with a high efficiency of 90 to 95% or more and also has outstanding heat stability. A heterodimer heavy chain constant region including the CH3 domain heterodimer can construct a bispecific monoclonal antibody which simultaneously recognizes two kinds of antigens. The CH3 domain heterodimer and the bispecific antibody or fusion protein of an antibody constant region comprising same can be usefully applied to the treatment or prevention of a disease associated with a target antigen or a target protein. | 10-29-2015 |
20150315281 | ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME - Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided. | 11-05-2015 |
20150315294 | ACCEPTOR FRAMEWORK FOR CDR GRAFTING - The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications. | 11-05-2015 |
20150322139 | METHODS FOR REDUCING GLYCOPROTEIN AGGREGATION - The present invention provides methods for reducing glycoprotein aggregation by optimizing the number of O-linked glycosylation sites. | 11-12-2015 |
20150322150 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND ISOLATION OF CELL-MEMBRANE PROTEIN SPECIFIC BINDING MOIETIES - Disclosed are methods of identifying binding moieties that recognize antigens displayed on cells, such as membrane proteins or recombinant proteins that display eptiopes on the surface of cells. Binding moieties capable of binding membrane proteins can be difficult to obtain because these proteins can depend on their native environments for structural integrity. In some methods scFv phage display libraries are panned against whole cells expressing a membrane protein in an emulsion. Certain methods further permit discrimination of binding moieties according to their affinity or avidity for a target. This approach allows rapid identification of cell surface epitope specific antibodies for research, diagnostics, and immunotherapeutics. | 11-12-2015 |
20150322154 | HLA-RESTRICTED, PEPTIDE-SPECIFIC BINDING PROTEINS - Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function. | 11-12-2015 |
20150322156 | FRAGMENT OF HUMANIZED ANTI-EGFR ANTIBODY SUBSTITUTED-LYSINE VARIABLE FRAGMENT AND USE THEREOF - The purpose of the present invention is to provide fragments of humanized anti-EGFR antibody substituted-lysine light-chain or heavy-chain variable regions, and single-chain antibodies, etc, comprising the same, having sufficient binding activity (affinity) with target cells, and having the ability to undergo various site-specific and uniform chemical modifications. The present invention pertains to a humanized variable region on the light-chain or heavy-chain of antibody 528 against human epidermal cell growth factor receptor 1 (Her-1), said variable region comprising the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, wherein fragments of humanized anti-EGFR antibody lysine-substituted light-chain variable regions are formed by substituting a different amino acid for all of the lysine residues, or all of the lysine residues except for the lysine residue(s) of one specified moiety. | 11-12-2015 |
20150322168 | In Vivo Method for Generating Diversity in a Protein Scaffold - A transgenic non-human animal is provided. In certain embodiments, the animal comprises a genome comprising an immunoglobulin heavy chain locus comprising: a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: i. a scaffold comprising a first binding domain; and ii. a heavy chain constant region operably linked to the scaffold; wherein the scaffold is capable of specifically binding to a target in the absence of additional polypeptides; and b) a plurality of pseudogenes that are operably linked to the transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of the transcribed gene that encodes the binding domain. | 11-12-2015 |
20150329634 | Anti-IL-23 Antibodies, Compositions, Methods and Uses - An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 11-19-2015 |
20150337034 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION - Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins. | 11-26-2015 |
20150337040 | METHODS OF PRODUCING IMMUNOCONJUGATES - The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods. | 11-26-2015 |
20150337046 | ANTAGONISTIC HUMAN LIGHT-SPECIFIC HUMAN MONOCLONAL ANTIBODIES - Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental. | 11-26-2015 |
20150337048 | ANTI-CD324 MONOCLONAL ANTIBODIES AND USES THEREOF - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 11-26-2015 |
20150344589 | PHOSPHOHISTIDINE ANALOGS - The present invention relates to the phosphohistidine analogs of the present invention which of the formula | 12-03-2015 |
20150344871 | System and Methods for Massively Parallel Analysis of Nucleic Acids in Single Cells - Methods and systems are provided for massively parallel genetic analysis of single cells in emulsion droplets or reaction containers. Genetic loci of interest are targeted in a single cell using a set of probes, and a fusion complex is formed by molecular linkage and amplification techniques. Methods are provided for high-throughput, massively parallel analysis of the fusion complex in a single cell in a population of at least 10,000 cells. Also provided are methods for tracing genetic information back to a cell using barcode sequences. | 12-03-2015 |
20150353940 | VECTORS FOR USE IN AN INDUCIBLE COEXPRESSION SYSTEM - The present invention provides expression vectors for use in an inducible coexpression system, capable of controlled induction of expression of each gene product. | 12-10-2015 |
20150361130 | Capture Purification Processes for Proteins Expressed in a Non-Mammalian System - Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. Resin regeneration methods are also provided. | 12-17-2015 |
20150361175 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION - Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins. | 12-17-2015 |
20150361421 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION - Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins. | 12-17-2015 |
20150368292 | METHOD OF PRODUCING A PROTEIN - The present invention relates to a method of producing a recombinant protein by harvesting a microbial cell broth and adding an amount of a flocculant to achieve an effective particle size distribution. The present invention also relates to a method of clarifying a microbial harvest by adding an amount of a flocculant to achieve an effective particle size distribution. | 12-24-2015 |
20150368317 | METHODS RELATED TO CTLA4-FC FUSION PROTEINS - The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) a CTLA4-Fc fusion protein, e.g., abatacept. In some instances, methods herein allow highly resolved evaluation of abatacept useful for, inter alia, manufacturing abatacept, characterizing abatacept, identifying and/or confirming abatacept, monitoring the structure of abatacept, comparing abatacept preparations made over time or made under different conditions, and/or controlling the structure of abatacept. | 12-24-2015 |
20150368345 | ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION - The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of lgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed. | 12-24-2015 |
20150368352 | NOVEL MULTISPECIFIC CONSTRUCTS - Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (ADCs), and methods of using such antibodies and ADCs to treat cancer. IgG-like bispecific antibodies have different binding specificities on each arm of the antibody. They are similar in structure to monospecific IgGs in that they contain two heavy chains with VH, CH1, CH2 and CH3 regions, and two light chains with VL and CL regions. | 12-24-2015 |
20150368363 | USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES - The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition. | 12-24-2015 |
20150376229 | TANGENTIAL FLOW FILTRATION BASED PROTEIN REFOLDING METHODS - Provided herein are methods for refolding proteins that are denatured. Exemplary methods comprise solubilizing the denatured protein with a denaturing agent, e.g., a chaotropic agent, and renaturing the protein using a buffer exchanging system, e.g., tangential flow filtration (TFF). | 12-31-2015 |
20150376273 | ANTIBODIES TO NTB-A - Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A. | 12-31-2015 |
20150376295 | Humanized Anti-Factor D Antibodies And Uses Thereof - The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 12-31-2015 |
20160002321 | MONOCLONAL ANTIBODIES TO ANTHRAX PROTECTIVE ANTIGEN - The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a | 01-07-2016 |
20160002334 | BI-SPECIFIC ANTIBODIES AGAINST TIM-3 AND PD-1 FOR IMMUNOTHERAPY IN CHRONIC IMMUNE CONDITIONS - Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer. | 01-07-2016 |
20160002356 | COILED COIL AND/OR TETHER CONTAINING PROTEIN COMPLEXES AND USES THEREOF - The invention provides engineered protein complexes constructed using a coiled coil and/or a tether and methods for making, using, and purifying such complexes, such as multispecific antibodies or other multispecific Fc containing complexes. | 01-07-2016 |
20160009799 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER | 01-14-2016 |
20160009818 | Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics | 01-14-2016 |
20160009820 | ANTI-FGFR2 ANTIBODY | 01-14-2016 |
20160017031 | T CELL RECEPTOR MIMIC RL9A - The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such that the molecules may be used as therapeutic, diagnostic and research reagents. The method of producing a T-cell receptor mimic of the present invention includes identifying a peptide of interest, wherein the peptide of interest is capable of being presented by an MHC molecule. Then, an immunogen comprising at least one peptide/MHC complex is formed, wherein the peptide of the peptide/MHC complex is the peptide of interest. An effective amount of the immunogen is then administered to a host for eliciting an immune response, and serum collected from the host is assayed to determine if desired antibodies that recognize a three-dimensional presentation of the peptide in the binding groove of the MHC molecule are being produced. The desired antibodies can differentiate the peptide/MHC complex from the MHC molecule alone, the peptide alone, and a complex of MHC and irrelevant peptide. Finally, the desired antibodies are isolated. | 01-21-2016 |
20160024144 | REMOVAL OF LEAKED AFFINITY PURIFICATION LIGAND - The invention provides for the removal of a large fraction of contaminants from protein preparations while maintaining a high level of recovery using tentacle anion exchange matrix chromatography medium. Using the methods of the invention, leached affinity chromatography contaminants can be removed from recombinant protein preparations. | 01-28-2016 |
20160024145 | HYDROPHOBIC INTERACTION PROTEIN CHROMATOGRAPHY UNDER NO-SALT CONDITIONS - Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions. | 01-28-2016 |
20160024146 | METHODS FOR PURIFYING ANTIBODIES - A method for purifying a protein comprising an antibody, antibody fragment, or immunoglobulin single variable domain, from a solution containing at least one contaminant by superantigen chromatography comprising: a) adsorbing the protein to the superantigen immobilized on a solid support; b) removing the at least one contaminant by contacting the immobilized superantigen containing the adsorbed protein with a first wash buffer comprising an aliphatic carboxylate; and c) eluting the protein from the superantigen immobilized on the solid support. | 01-28-2016 |
20160024147 | Purification Platform for Bispecific Antibodies - High resolution protein A chromatography employing a chaotropic agent and pH gradient or pH step elution buffer results in improved peak resolution between closely related molecular species. Bispecific antibodies containing a protein A-binding-ablating substitution CH3 domain paired with a protein A-binding CH3 domain are separated with high peak resolution from monospecific antibodies containing a protein A-binding-ablating substituted CH3 domain paired with the protein A-binding-ablating substituted CH3 domain and monospecific antibodies containing a protein A-binding CH3 domain paired with the protein A-binding CH3 domain. Useful chaotropic agents include magnesium chloride and calcium chloride. | 01-28-2016 |
20160024158 | Inhibitory Polypeptides Specific to WNT Inhibitors - The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them. | 01-28-2016 |
20160031975 | Compositions and Methods for Antibodies Targeting Complement Protein C5 - The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof. | 02-04-2016 |
20160031980 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION - Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins. | 02-04-2016 |
20160031997 | METHODS AND COMPOSITIONS RELATING TO ANTI-CCR7 ANTIGEN BINDING PROTEINS - The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins. | 02-04-2016 |
20160032007 | Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4) - Human antibody fragments against chrondroitin sulfate proteoglycan 4 can be used to deliver cytotoxic agents to cells which express CSPG4. The agents can be diagnostic or therapeutic moieties. They may be linked by covalent or non-covalent linkages to the antibody fragments. They may be produced as a genetic fusion product or joined together synthetically, for example. When the human antibody fragments are internalized by the cells to which they bind, they can carry with them the attached agents. Thus toxic agents having intracellular targets have enhanced killing upon internalization. | 02-04-2016 |
20160039935 | NOVEL ANTI-cMET ANTIBODY - The present invention relates to a novel divalent antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, preferably both in a ligand-dependent and in a ligand-independent manner as well as the amino acid and nucleic acid sequences coding for said antibody. More preferably said antibody comprises a modified hinge region and exhibits an improved antagonistic activity. More particularly, the antibody according to the invention is capable of inhibiting the c-Met dimerization. The invention likewise comprises the use of said antibody as a medicament for the prophylactic and/or therapeutic treatment of cancers, preferably for cancer characterized by a ligand-independent activation of c-Met, or any pathology connected with the over expression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the over-expression of c-Met. The invention finally comprises products and/or compositions comprising such an antibody in combination with other antibodies and/or chemical compounds directed against other growth factors involved in tumor progression or metastasis and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 02-11-2016 |
20160039947 | METHODS FOR PRODUCING FABS AND BI-SPECIFIC ANTIBODIES - The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (V | 02-11-2016 |
20160046698 | Methods and Compositions Related to Immunizing Against Staphylococcal Lung Diseases and Conditions - Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing Hla to provide immunoprotection against | 02-18-2016 |
20160053015 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 02-25-2016 |
20160053018 | ANTI-HUMAN TROP-2 ANTIBODY HAVING ANTI-TUMOR ACTIVITY IN VIVO - The present invention provides: an antibody, which specifically reacts with hTROP-2 and has anti-tumor activity in vivo; a hybridoma, which produces the aforementioned antibody; a complex of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor. | 02-25-2016 |
20160060348 | ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND USE IN THERAPY - Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein. | 03-03-2016 |
20160060349 | METHOD FOR INCREASING PYRO-GLUTAMIC ACID FORMATION OF A PROTEIN - A method for conversion of an N-terminal glutamine and/or glutamic acid residue of a protein to pyro-glutamic acid within a purification process. | 03-03-2016 |
20160060353 | ANTI-HER2 ANTIBODY VARIANTS - The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains | 03-03-2016 |
20160068586 | PD-1 ANTIBODIES - A humanised agonistic antibody which binds human PD-1 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:7 for CDR-L3. The invention also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules. | 03-10-2016 |
20160068589 | IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES - Anti-SpA murine, chimeric and humanized monoclonal antibodies, and variant antibodies having a heavy chain with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections. | 03-10-2016 |
20160075782 | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1) - The present disclosure provides isolated monoclonal antibodies particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies. | 03-17-2016 |
20160083453 | SEPARATION OF RECOMBINANT POLYCLONAL ANTIBODY MULTIMERS WITH MINIMAL SEPARATION OF MONOMERS - The invention provides a method for removing multimers from a preparation of recombinant polyclonal antibodies (rpAbs) while maintaining the ratio of monomers within a narrow range. The invention provides a method of separating recombinant polyclonal antibody multimers with minimal separation of monomers comprising subjecting a mixture comprising a plurality of monoclonal antibodies to at least one separation process selected from the group consisting of multi-modal chromatography, apatite chromatography, and hydrophobic interaction chromatography thereby producing an antibody monomer preparation that is substantially free of multimers. | 03-24-2016 |
20160083476 | PRODUCTION OF ANTIBODY FORMATS AND IMMUNOLOGICAL APPLICATIONS OF SAID FORMATS - The invention concerns antibody formats comprising VHsequence of Camelidae, such as llamas; antibodies of various formats have anti-CEA or anti-CD16 VH sequences thereof; vectors expressing the antibody formats, and methods for producing the same. | 03-24-2016 |
20160090426 | Construction and application of bispecific antibody EpCAMxCD3 - The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against surface antigen CD3 of an immune cell; the monovalent unit has a specific binding capability against the surface antigen EpCAM of a tumor cell; the single-chain unit comprises a single-chain variable fragment ScFv fused with an Fc fragment; and the monovalent unit comprises a light chain and heavy chain pair. The present invention also provides a preparation method of the bispecific antibody and pharmaceutical use of these antibodies. | 03-31-2016 |
20160096876 | COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein. | 04-07-2016 |
20160096898 | PC33718E - The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia. | 04-07-2016 |
20160102137 | CROSSLINKED ANTI-HIV-1 COMPOSITIONS FOR POTENT AND BROAD NEUTRALIZATION - An anti-HIV-1 spike composition includes a first anti-HIV-1 antibody Fab and a second anti-HIV-1 antibody Fab linked by a DNA or protein linker molecule to form a crosslinked homo-diFab or hetero-diFab having improved viral potency and neutralization. The anti-HIV-1 antibody Fabs include anti-gp120 CD4, anti-gp120 V1V2, anti-gp120 V3, and anti-gp41. | 04-14-2016 |
20160102146 | ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same. | 04-14-2016 |
20160102148 | MODIFIED ANTIBODY IN WHICH MOTIF COMPRISING CYSTEINE RESIDUE IS BOUND, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING THE MODIFIED ANTIBODY, AND PRODUCTION METHOD FOR SAME - The present invention relates to an antibody in which a motif composed of an amino acid or peptide sequence including one or more cysteine residues is bound to the terminus of a parent antibody, particularly the terminus of the heavy chain of the parent antibody. Also, the present invention relates to a modified antibody-drug conjugate (mADC) comprising a drug bound to the antibody, and a method for producing the antibody or the modified antibody-drug conjugate. The modified antibody-drug conjugate according to the invention can accurately deliver the drug to a target cell due its high specificity to antigen, and thus can increase the therapeutic effect of the drug. Also, it can increase the usability of drugs, particularly anticancer drugs, the use of which is restricted due to their toxicity, despite their high efficacy. Moreover, the invention relates to a composition for treatment of diseases, particularly cancers, which comprise the modified antibody-drug conjugate. | 04-14-2016 |
20160102333 | QUANTITATIVE CONTROL OF SIALYLATION AND SPECIFIC MONO-SIALYLATION - The present disclosure is directed to the use of certain glycosyltransferase variants having N-terminal truncation deletions. It was found that the combination of two different truncation variants of human β-galactoside-α-2,6-sialyltransferase I (hST6Gal-I) exhibited different specific sialyltransferase enzymatic activities. In one example, under conditions wherein the first variant Δ89 hST6Gal-I catalyzed formation of bi-sialylated target molecules the second variant Δ108 hST6Gal-I catalyzed formation of mono-sialylated target molecules. Thus, disclosed are variants of mammalian glycosyltransferase, nucleic acids encoding the same, methods and means for recombinantly producing the variants of mammalian glycosyltransferase and use thereof, particularly for sialylating in a quantitatively controlled manner terminal acceptor groups of glycan moieties being part of glycoproteins such as immunoglobulins. | 04-14-2016 |
20160108105 | HUMAN IGG4 FC POLYPEPTIDE VARIANT - Disclosed is a human IgG4 Fc polypeptide variant, including a modified CH2 domain of human IgG4 Fc, wherein the modification contains a replacement of a 6-20 consecutive amino acid sequence from the N-terminus of the CH2 domain of IgG4 with a 4-18 consecutive amino acid sequence from the N-terminus of human IgA1 CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgA2 CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgD CH2, a 4-18 consecutive amino acid sequence from the N-terminus of human IgE CH2, or a 4-18 consecutive amino acid sequence from the N-terminus of human IgM CH2. The Fc variant imparts to a biologically active polypeptide—the modified Fc variant with a prolonged in-vivo half-life and reduced immunogenic reaction. | 04-21-2016 |
20160108111 | METHODS OF SHIFTING AN ISOELECTRIC PROFILE OF A PROTEIN PRODUCT AND USES THEREOF - Provided herein are methods shifting the isoelectric profile of a recombinant protein product and the use of such methods in the manufacture of recombinant protein products. Also provided are recombinant protein products produced by such methods. | 04-21-2016 |
20160108450 | SIALYLATED GLYCOPROTEINS - Glycoproteins having particular sialylation patterns, and methods of making and using such glycoproteins, are described. | 04-21-2016 |
20160115195 | PURIFICATION PROCESS FOR MONOCLONAL ANTIBODIES - The present invention provides an improved method for the purification of monoclonal antibody from cell culture. Process of purification of the desired monoclonal antibody comprises affinity, hydrophobic interaction and optionally ion exchange column chromatography. It provides more than 99% purity of the desired monoclonal antibody. | 04-28-2016 |
20160115222 | IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES - Anti-SpA murine, chimeric and humanized monoclonal antibodies, and variant antibodies having a heavy chain with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections. | 04-28-2016 |
20160122384 | Method For Purifying Antibody - The present invention relates to a method of purifying an antibody with high purity and high quality by removing impurities by sequential use of a cation-exchange column, a culture supernatant multilayer filter and an anion-exchange column without using a protein-A column that is an affinity chromatography column which is generally used for antibody purification. | 05-05-2016 |
20160122385 | METHODS OF INCREASING PROTEIN PURITY USING PROTEIN A BASED CHROMATOGRAPHY - The present invention provides methods for increasing purity of an Fc-containing protein by removing protein aggregates during the Protein A chromatography step used during the purification of the Fc-containing protein. | 05-05-2016 |
20160122425 | Activatable Binding Polypeptides and Methods of Identification and Use Thereof - Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use. | 05-05-2016 |
20160122427 | Protein Production Method - Production of etanercept using perfusion methods achieves attractive yields of properly folded protein. Desired temperature, feed media, titers and percent correctly folded protein are disclosed. | 05-05-2016 |
20160130320 | MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES - The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component. | 05-12-2016 |
20160130327 | CMV NEUTRALIZING ANTIGEN BINDING PROTEINS - The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof. | 05-12-2016 |
20160130331 | MULTIVALENT DLL3 ANTIBODIES - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 05-12-2016 |
20160130339 | Isolation and Purification of Anti-IL-13 Antibodies Using Protein A Affinity Chromatography - Disclosed herein are methods for the isolation and purification of anti-IL-13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography (e.g., Protein A affinity chromatography), ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention. | 05-12-2016 |
20160130358 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES - Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. | 05-12-2016 |
20160138065 | METHODS FOR CONTROLLING FUCOSYLATION LEVELS IN PROTEINS - The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or a eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions. | 05-19-2016 |
20160145323 | ANTIBODIES AGAINST CHIKUNGUNYA VIRUS AND USES THEREOF - Embodiments disclosed herein provide for antibodies, including neutralizing antibodies, against Chikungunya virus, uses thereof, and methods of identifying antibodies, including neutralizing antibodies, against Chikungunya virus. In some embodiments, antibodies that binds to a CHIKV antigen, wherein the antigen is the CHIKV E1, E2, E3 protein, or any heterocomplex thereof are provided. In some embodiments, the antibody is an isolated antibody, a neutralizing antibody, a recombinant antibody, or any combination thereof. In some embodiments, the antibodies described herein bind to an epitope of E2 Domain A, E2 Domain B, or E1 Domain II of the CHIKV antigen. In some embodiments, the antigen is E2 protein. | 05-26-2016 |
20160145330 | NOVEL POLYPEPTIDE, AND USE THEREOF - This invention provides a novel means that allows efficient secretion and production of a target protein in a host cell. This invention concerns a novel polypeptide having an activity of improving the secretion productivity of a target protein, a gene comprising a nucleotide sequence encoding such polypeptide, a vector comprising such gene, a transformant obtained by transforming a host cell with such vector, and a method for producing a protein comprising a step of culturing such transformant and recovering a target protein from the culture product. | 05-26-2016 |
20160145339 | Construction and application of bispecific antibody HER2xCD3 - The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against a surface antigen CD3 of an immune cell; the monovalent unit has a specific binding capability against a surface antigen HER2 of a tumor cell; the single-chain unit comprises a single-chain variable fragment ScFv fused with an Fc fragment; and the monovalent unit comprises a light chain and heavy chain pair. The present invention also provides a preparation method of the bispecific antibody and pharmaceutical use of these antibodies. | 05-26-2016 |
20160152684 | IMMUNOGLOBULIN FC CONJUGATE WHICH MAINTAINS BINDING AFFINITY OF IMMUNOGLOBULIN FC FRAGMENT TO FCRN | 06-02-2016 |
20160152694 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF | 06-02-2016 |
20160152700 | Antigen Binding Proteins Capable of Binding Thymic Stromal Lymphopoietin | 06-02-2016 |
20160152701 | INDUCIBLE EXPRESSION SYSTEM | 06-02-2016 |
20160152711 | DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES | 06-02-2016 |
20160152716 | METHODS FOR IDENTIFYING IMMUNOBINDERS OF CELL-SURFACE ANTIGENS | 06-02-2016 |
20160152726 | PROTEIN IN WHICH ELECTRICAL INTERACTION IS INTRODUCED WITHIN HYDROPHOBIC INTERACTION SITE AND PREPARATION METHOD THEREFOR | 06-02-2016 |
20160153020 | METHODS FOR PRODUCING SIALYLATED THERAPEUTIC PROTEINS | 06-02-2016 |
20160159878 | NOGO Receptor Antagonists - Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides. | 06-09-2016 |
20160159887 | IMMUNOTHERAPY AND DIAGNOSIS OF MUCORMYCOSIS USING COTH - The invention provided Mucorales CotH antibodies, polypeptides, encoding nucleic acid molecules, and uses thereof. The Mucorales CotH antibodies, polypeptides and encoding nucleic acids disclosed herein can be advantageously used to diagnose, treat or prevent fungal conditions, in particular mucormycosis. | 06-09-2016 |
20160159915 | ANTIBODY CONSTANT REGION VARIANT - By means of amino acid sequence alterations, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated. | 06-09-2016 |
20160168213 | GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTS | 06-16-2016 |
20160176921 | METHODS OF PURIFYING RECOMBINANT PROTEINS | 06-23-2016 |
20160176981 | ANTI-GD2 ANTIBODIES | 06-23-2016 |
20160176982 | Fc VARIANTS WITH ALTERED BINDING TO FcRn | 06-23-2016 |
20160185841 | METHOD FOR PURIFYING ANTIBODIES USING PBS - Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris). | 06-30-2016 |
20160185860 | MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. | 06-30-2016 |
20160185876 | HUMANIZED ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY - A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin. | 06-30-2016 |
20160193295 | STABILIZATION OF FC-CONTAINING POLYPEPTIDES | 07-07-2016 |
20160200777 | METHIONYL TRNA SYNTHETASE FOR BIOSYNTHESIS OF PHOTOMETHIONINE-LABELED PROTEIN AND METHOD FOR PREPARING PHOTOACTIVE PROTEIN G VARIANT USING SAME | 07-14-2016 |
20160200799 | ANTI-INFLUENZA VIRUS NEUTRALIZING ANTIBODY | 07-14-2016 |
20160251336 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | 09-01-2016 |
20160251395 | READILY ISOLATED BISPECIFIC ANTIBODIES WITH NATIVE IMMUNOGLOBULIN FORMAT | 09-01-2016 |
20160376304 | SEPARATION OF BISPECIFIC ANTIBODIES AND BISPECIFIC ANTIBODY PRODUCTION SIDE PRODUCTS USING HYDROXYAPATITE CHROMATOGRAPHY - The present invention is directed to methods comprising the use of hydroxyapatite chromatography to separate a bispecific antibody from a solution that also comprises one or more byproducts specific to bispecific antibody production. Byproducts specific to the production of bispecific antibodies (bispecific antibody specific byproducts, “BASB”) include fragments of the bispecific antibody and heavier molecular weight variants of the antibody, wherein the fragment and/or variant comprises an Fc domain but does not exhibit affinity for the two different epitopes and/or antigens as exhibited by the desired bispecific antibody. Thus, the methods of the present invention comprise the separation of a bispecific antibody from one or more of its BASB. The hydroxyapatite chromatography methods of the invention may be used alone or may be further combined with standard purification processes and unit operations as is known in the art to achieve any level of purity of bispecific antibody necessary, e.g., for therapeutic and/or diagnostic applications. | 12-29-2016 |
20160376349 | Compositions For diagnosis and Therapy of diseases associated with aberrant expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 12-29-2016 |
20160376359 | ANTI-HUMAN PROBDNF MONOCLONAL ANTIBODY, AND USES THEREOF IN PAINS - The present invention provides an anti-human proBDNF monoclonal antibody, and uses thereof in pains. Specifically, the present invention provides uses of antibody polypeptide of tenth to 128 | 12-29-2016 |
20160376370 | INTERFERON RECEPTOR 1 ANTIBODIES AND THEIR USES - The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention. | 12-29-2016 |
20160376570 | O-Mannosyltransferase Deficient Filamentous Fungal Cells and Methods of Use Thereof - The present disclosure relates to compositions and methods useful for the production of heterologous proteins with reduced O-mannosylation in filamentous fungal cells, such as | 12-29-2016 |
20170233453 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS | 08-17-2017 |
20170233457 | Immunoglobulin Variable Region Libraries | 08-17-2017 |
20180022794 | ANTI-RHO GTPASE CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF | 01-25-2018 |
20180022798 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION | 01-25-2018 |
20190144493 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | 05-16-2019 |
20190144495 | HYDROPHOBIC INTERACTION PROTEIN CHROMATOGRAPHY UNDER NO-SALT CONDITIONS | 05-16-2019 |
20190144515 | MODIFIED CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | 05-16-2019 |
20190144541 | ANTI-PD-1 MONOCLONAL ANTIBODY AND OBTAINING METHOD THEREFOR | 05-16-2019 |
20190144872 | Generating Targeted Sequence Diversity in Fusion Proteins | 05-16-2019 |
20220135618 | POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS - The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies. | 05-05-2022 |
20220135684 | BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28 - Provided herein are novel αPD-L1 antibodies and methods of using such antibodies for the treatment of cancers. In some embodiments, the antibodies are αPD-L1×αCD28 bispecific antibodies. Such antibodies enhance anti-tumor activity by providing a costimulatory signal for T-cell activation against tumor cells while advantageously also blocking inhibitory PD-L1:PD-1 pathway interactions. | 05-05-2022 |